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ABSTRACT 
 
 
Cardiovascular disease is a leading cause of death and hospitalizations in Canada.  Most risk 
factors for cardiovascular disease are known, and many are modifiable.  One such risk factor that 
often goes unrecognized is non-adherence.  Pharmacists are ideally positioned to have an 
influence on cardiovascular risk reduction, including supporting medication adherence; however 
it is still unknown whether typical (non-specialist) pharmacists can provide strategies that are 
effective and sustainable in today’s health care system.  Thus, the overall objective of this 
research project was to determine what interventions typical pharmacists can adopt to effectively 
facilitate cardiovascular risk reduction within the constraints of the current practice environment.  
This objective was accomplished through 4 related studies: 1) a randomized controlled trial 
involving a pharmacist-directed cardiovascular risk reduction collaboration within a family 
physician practice; 2) a systematic review identifying and evaluating published interventions by 
community pharmacists for cardiovascular disease or diabetes; 3) the design of a pilot study 
evaluating a novel community pharmacy intervention aimed at cardiovascular risk reduction and; 
4) the examination of adherence patterns among antihypertensive medication users to identify 
associated factors and high-risk periods for non-adherence. 
 
Although the randomized controlled trial did not show a statistically significant benefit of the 
pharmacist intervention on cardiovascular risk, it did demonstrate the feasibility of incorporating 
a pharmacist into a collaborative role, without the need for an advanced or specialized degree.  
Results from the systematic review yielded several studies involving community pharmacists and 
cardiovascular disease or diabetes.  However, the majority of these studies were of poor quality, 
evaluated complex and intensive interventions, and provided questionable clinical benefits.  The 
design of the pilot study demonstrated the feasibility of developing high quality, robust research 
involving community pharmacists.  Finally, the observational study examining adherence 
patterns to antihypertensive agents revealed two important findings that can guide the 
development of future strategies to support adherence: the first year of therapy, and particularly 
the first dispensation, is a critical time for the development of non-adherence and, contrary to 
previously published studies, adherence is similar between all classes of antihypertensive 
medications.  
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This program of research did not identify one particular pharmacist intervention as being 
superior for cardiovascular risk reduction in today’s practice environment.  However, it did 
highlight the need for improved study quality and the development of interventions that are 
practical and can be realistically implemented by pharmacists in today’s practice environment.  
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- Chapter 1 - 
INTRODUCTION  
 
1.1 Rationale 
Chronic diseases are the leading cause of death and disability in Canada.1  It is estimated that 
65% of Canadians have at least one risk factor for the development of a chronic disease, and that 
over 50% of the population is already living with one.1  Besides directly affecting individual 
quality of life, chronic diseases monopolize health care spending.  Seventy-seven billion dollars, 
almost half of the annual cost of illness in Canada, is spent yearly on chronic diseases.1  
Although numerous chronic diseases exist, only five account for 99% of all related deaths: 
cancer, respiratory illness, diabetes, mental disorders, and cardiovascular disease (CVD).1  
 
Cardiovascular disease is an all-encompassing term which includes any disease affecting the 
heart or blood vessels.2  Despite well known risk factors and evidence based strategies, it 
remains the leading cause of death and hospitalization throughout the developed world.3-5  Also, 
it is the most expensive chronic disease in Canada, costing just under $20.6 billion in 1998.6   
Cardiovascular disease consumes acute health care services, increases the need for chronic care 
services including cardiac rehabilitation, outpatient physician visits, medication, and laboratory 
services, and is associated with indirect costs due to productivity losses and premature 
mortality.6   
 
This humanistic and economic burden is troubling as many CVDs are largely preventable.7  
Widely recognized epidemiological research, started over 50 years ago with the Framingham 
Study, has identified modifiable predisposing factors to both ischemic heart disease and stroke, 
which are collectively known as atherosclerotic cardiovascular disease (A-CVD).8  Risk factors 
for A-CVD are also important for other cardiovascular diseases; thus risk factor modification has 
the potential to protect against multiple adverse outcomes.   
 
In clinical practice, it is recommended that all men over 40 years of age and women who are 
over 50 years of age or post-menopausal should be routinely screened for A-CVD.9  Canadian 
guidelines also recommend screening those with: diabetes mellitus; risk factors such as 
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hypertension, smoking, or abdominal obesity; hyperlipidemia; evidence of atherosclerosis; or a 
strong family history of premature A-CVD.9  Despite a wealth of information about risk factors, 
screening recommendations and effective treatment strategies,9-11 there is overwhelming 
evidence that modifications of cardiovascular risk factors, whether behavioural or 
pharmacological, are not successfully undertaken in the majority of patients at risk.4, 12-23   
 
1.2 Non-Adherence to Cardiovascular Medications  
Another risk factor for A-CVD that often goes unrecognized is non-adherence.24  Adherence is 
defined as the extent to which a person’s behaviour, taking medication, following a diet, and/or 
executing lifestyle changes, corresponds with agreed recommendations from a health care 
provider.25 The reasons for non-adherence are complex, and it is a major health issue that has 
been observed worldwide.25  It is estimated that 50% of patients are non-adherent to chronic 
medications,26 and only 10% are adherent to lifestyle or behavioural modifications over the long 
term.26  Non-adherence is frequently identified by physicians as a significant barrier to 
employing guideline-directed preventative care,27 and has been implicated as a major reason for 
suboptimal outcomes,21, 25, 28 decreased patient quality of life, death, and wasted health care 
resources.25, 29-31  In Canada, non-adherence costs approximately $8 - 10 billion every year.32  
 
Management of A-CVD requires multiple, costly, life-long medications which pose both an 
inconvenience and financial burden to many patients.33  Also, patient confidence in prescribers 
as well as beliefs about the effectiveness, safety or necessity of prescriptions or treatments can 
affect adherence.34, 35   Multiple media sources convey negative messages about prescription 
medications and health care providers appear to have little opportunity to counter them.  Not 
surprisingly, approximately 50% of individuals do not adhere to their cardiovascular 
medications.26, 36  Much of this non-adherence occurs within the first two years of therapy,36-39 
and has been specifically associated with increases in morbidity, mortality, cardiovascular-
related hospitalizations and coronary revascularization procedures.21, 31, 40   
 
1.3 Role of Pharmacy in Cardiovascular Disease Risk Reduction  
Because the management of A-CVD is a complex process,41 multidisciplinary approaches have 
been recommended to improve the success of risk factor modification.42  Several organizations 
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have suggested that pharmacists, especially those in primary care or community settings, should 
play a more active role in the management of A-CVD43-46 because of their accessibility,47 
frequent contact with patients, and strong knowledge of pharmacotherapy.  Indeed, many studies 
have examined pharmacist interventions aimed at improving A-CVD management;18, 47-51 
however, few of these research protocols have ever been implemented in real-world settings.52 
 
The majority of published pharmacist interventions require close collaborations with physicians 
and/or frequent and intensive patient follow-up.18, 51, 53, 54  Unfortunately, the practice 
environment for most pharmacists in Canada is not conducive to either.  Although there has been 
a recent increase in the number of pharmacists working directly within medical practices, they 
are typically specialized or hold post-graduate degrees, whereas the majority of baccalaureate 
trained pharmacists still work in retail or community pharmacy settings.   
 
In community pharmacy settings, remuneration is primarily based on dispensing prescriptions; 
thus any activities related to non-dispensing activities, however worthwhile, are often not given 
priority.  The current pharmacist shortage is also a factor, as many pharmacists simply do not 
have the time necessary for program training, or implementation of intensive program protocols.  
As such, collaborations with physicians are generally limited to brief communications regarding 
technical issues related to prescription writing, and interactions with patients rarely go beyond 
basic counselling at prescription dispensations.  Similarly, the extent to which pharmacists 
engage patients for the purpose of supporting adherence is unknown, although, anecdotally, rates 
appear to be extremely low.   
 
1.4 Summary 
Pharmacists in primary care or community pharmacy settings are ideally positioned to have a 
major influence on cardiovascular risk reduction, including supporting medication adherence.  
However, it is still unknown whether pharmacists can provide cardiovascular risk-reduction 
strategies that are effective and sustainable in today’s health care system.  Given its high 
prevalence and significant clinical and economic impact, routinely preventing even a fraction of 
A-CVD, and related non-adherence, may have a major impact.  Therefore, further research is 
needed to identify practical ways that pharmacists can successfully employ cardiovascular risk 
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reduction strategies that are feasible and sustainable in the current health care system and 
practice environment. 
 
1.5 Research Question 
What strategic interventions can typical (non-specialist) pharmacists in primary care settings 
adopt to effectively facilitate cardiovascular risk reduction within the constraints of the current 
health care system and practice environment? 
 
1.6 Research Objectives 
The objectives of this program of research were: 1) to evaluate a randomized controlled trial 
involving a pharmacist-directed cardiovascular risk reduction collaboration within a family 
physician practice; 2) to systematically review the literature to identify and evaluate published 
interventions by community pharmacists for the purpose of diabetes or cardiovascular disease 
risk reduction and/or management; 3) to design a cluster randomized controlled pilot study to 
objectively evaluate a community pharmacy cardiovascular risk reduction intervention and; 4) to 
use Saskatchewan Health data to examine adherence patterns among antihypertensive medication 
users, and to verify and/or identify high-risk periods for non-adherence.  
 
1.7 Program of Research 
This thesis is composed of four separate but related studies, each addressing a specific research 
objective, in an attempt to answer the original research question: what strategic interventions can 
typical pharmacists in primary care settings adopt to effectively facilitate cardiovascular risk 
reduction within the constraints of the current health care system and practice environment?  
The first study (Chapter 2) looks at the role of pharmacy in a primary care setting through a 
randomized controlled trial evaluating a pharmacist-directed cardiovascular risk reduction 
collaboration within a family physician practice.  Chapter 3 looks specifically at community 
pharmacists, by systematically reviewing published interventions involving community 
pharmacists aimed at the risk reduction or management of cardiovascular disease or diabetes.  
Subsequent to the findings of the systematic review, Chapter 4 is the methodology and study 
design of a pragmatic, province-wide cluster randomized trail to objectively evaluate a 
community pharmacy intervention aimed at improving adherence to a particular class of 
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cardiovascular medication (statins).  Finally, although a fair amount is known about adherence 
and utilization patterns of statin medications, little it known about other cardiovascular drugs.  
Chapter 5 is an observational study of administrative data from Saskatchewan that examines 
utilization patterns of antihypertensive medications to identify associated factors and high-risk 
periods for non-adherence.   
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- Chapter 2 - 
 
COLLABORATIVE CARDIOVASCULAR RISK-REDUCTION IN PRIMARY CARE: 
RESULTS OF THE CCARP STUDY 
 
 
2.1 Abstract 
 
Background:  Studies have demonstrated cardiovascular risk reduction success when 
pharmacists work in collaborative settings.  However, these protocols are often complex and may 
not be easily performed by non-specialized pharmacists.   
 
Objective: To evaluate whether a simple pharmacist protocol can significantly reduce 
cardiovascular risk in a large family medicine practice in Saskatoon, Saskatchewan, Canada. 
 
Methods:  Eligible patients initially met with the pharmacist to receive general counselling 
about cardiovascular disease.  Patients exhibiting a 10-year Framingham risk score ≥15%, or a 
coronary artery disease equivalent (coronary artery disease, peripheral artery disease, 
cerebrovascular disease, or diabetes mellitus), were randomized to receive ongoing follow-up 
(follow-up group) by the pharmacist, or to return to usual care (single contact group), and were 
followed for a minimum of 6 months.  The primary endpoint was the mean reduction in the 10-
year risk score.  Secondary endpoints included individual modifiable risk factors (systolic and 
diastolic blood pressure, total cholesterol, LDL-cholesterol, HDL-cholesterol, total 
cholesterol:HDL-cholesterol, and A1c), statin utilization, initiation and adherence rates.    
 
Results:  Baseline characteristics were similar across both groups (n=176).  Neither the mean 
reduction in 10-year risk (-2.68 and -1.25, respectively, one-tailed P=0.098) nor individual risk 
factors were significantly different between the follow-up and single contact groups.  The 
proportion of patients exhibiting adherence ≥ 80% did not differ at the study end (73.1% [57/78] 
and 80.0% [52/65] respectively, P=0.333).  However, 85.2% (75/88) in the follow-up group 
remained on statin therapy at the end of the study, compared to 67.0% (59/88) in the single 
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contact group (P=0.005).  Statin initiations in the follow-up group compared to the single contact 
group were 75.0% [30/40] and 48.9% [22/45], respectively, (P=0.013).   
 
Conclusion:   This simple cardiovascular care protocol for non-specialist pharmacists did not 
result in a clear improvement to cardiovascular risk reduction success among patients in a 
primary care medical clinic.  The intervention did, however, appear to improve statin utilization.    
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2.2 Introduction 
Despite well known risk factors and effective treatment strategies, cardiovascular disease (CVD) 
remains the leading cause of death in Canada and throughout the developed world.1, 2  Although 
multidisciplinary and collaborative protocols involving pharmacists have proven to enhance 
cardiovascular risk reduction success,3-5 the complexity and resources required for these 
strategies likely limits their uptake and sustainability in real-world settings.6  For example, Carter 
et al. demonstrated that clinical pharmacists could facilitate blood pressure reduction among 
patients in primary care clinics; however, the pharmacists and physicians were primarily 
academic faculty members, focused solely on blood pressure reduction, and managed only a 
small group of patients (n=77).7  Likely, the clinical protocol followed in this study would not be 
easily reproduced by a typical pharmacist without advanced clinical training.   
 
Although protocols such as these provide evidence for the benefits of high-level clinical 
collaborations, they may be too complex to serve as a general guide for all pharmacists, 
especially those without previous experience or advanced training.  For example, the majority of 
Canadian pharmacists practice in retail settings with little formal collaborative opportunities.  
Therefore, we developed a simple strategy for cardiovascular risk reduction that was designed 
for non-specialist pharmacists who have an opportunity to establish a new practice in primary 
care settings.  The goal of the strategy was to allow a pharmacist to contribute to a collaborative 
environment quickly without the need for advanced training.  We hypothesized that a ‘typical’ 
pharmacist could improve the success of cardiovascular risk reduction in most primary care 
settings by focusing on three specific tasks: screening and risk stratification; identification and 
reminders about uncontrolled risk factors; and adherence support.  The purpose of this pilot 
study was to evaluate the success of incorporating this strategy into a typical fee-for-service 
physician practice. 
 
2.3 Methods 
Study Setting 
This study was a prospective, randomized controlled pilot study that evaluated a pharmacist-led 
cardiovascular risk reduction strategy among patients attending a single large family medicine 
practice in Saskatoon, Saskatchewan, Canada.  At the time of the study (August 2006 to 
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December 2007), the family medicine practice was comprised of 12 general practitioners 
providing care to over 30,000 patients.  This practice had not previously employed a clinical 
pharmacist, and had no previous experience working with a pharmacist in this capacity.  Because 
of budget limitations, all study activities were provided by a single pharmacist who was also the 
lead investigator (CE).  Because this pharmacist was responsible for the development of the 
study, her training was more extensive than what would be needed to deliver this intervention.  
However, the intervention was designed so that subsequent pharmacist training would only 
require a review of cardiovascular risk factors, Framingham risk tools, and risk reduction 
therapies discussed in Canadian practice guidelines.8-11  In addition, the investigator was very 
careful to provide only those activities outlined by the protocol in order to test our hypothesis.  
Because our collaborative strategy required only basic activities to be performed, we believe the 
required training could be completed by pharmacists relatively quickly.  
 
Procedures 
Prior to its implementation, physicians were given a brief presentation about the proposed study 
and approved the protocol.  Patient recruitment was achieved through physician referral and 
advertisements placed in patient waiting areas.  Physicians were asked to refer all patients who 
exhibited any cardiovascular risk factors (hypertension, dyslipidemia, diabetes mellitus, or a 
previous cardiovascular event) to the study pharmacist.  Patients were provided with a written 
description of the study, including the consent form, and were contacted by the study pharmacist 
within one week to determine interest in enrollment.   
 
The pharmacist met with all study patients for an initial interview consisting of general 
counselling about cardiovascular disease.  This meeting lasted approximately 1 hour, at which 
time the pharmacist recorded drug therapies and determined the individual 10-year risk for 
cardiac death or non-fatal myocardial infarction based on the Framingham Risk Score (FRS) 
recommended by the Canadian Cardiovascular Society.8  All data collection was based on 
medical record review and patient interview; the pharmacist did not personally perform any 
physical assessment activities such as blood pressure measurement.  Basic CVD risk information 
was provided to all consenting individuals before randomization occurred.  All patients received 
an illustrated booklet that had been previously co-developed by one of the authors (CE).  The 
14 
 
 
 
booklet contained general information on the cardiovascular disease process, risk factors and 
emphasized the importance of achieving recommended targets for blood pressure, cholesterol, 
and A1c.  It also contained information about pharmacological management, as outlined by 
current practice guidelines (Appendix A).8-11      
 
Patients were randomly assigned to receive either follow-up with the pharmacist (follow-up 
group) or usual care (single contact group) if they met one of the following inclusion criteria: a 
calculated FRS of at least 15%, or a coronary artery disease risk equivalent (coronary artery 
disease, peripheral artery disease, cerebrovascular disease, or diabetes mellitus).8  Patients 
assigned to the single contact (usual care) group received no further contact with the study 
pharmacist.  Once randomization occurred, the pharmacist documented the treatment group 
assignment and the individual FRS in the medical record.  Randomization codes were kept in 
individually sealed envelopes and opened by the study pharmacist at the end of the initial visit.  
However, no attempt was made to blind any participant in the study.  Randomization lists were 
stratified by each physician and were created using a table of random numbers in permuted 
blocks of 4.  Patients were excluded if they had severe psychiatric conditions or dementia, 
symptomatic heart failure (NYHA class III or IV), terminal illness, concurrent participation in an 
investigational study, or women who were pregnant or breastfeeding.   
 
Study Activities 
For patients assigned to the follow-up group, the pharmacist established the following goals: 
blood pressure less than 130/80 mmHg for individuals with diabetes or chronic kidney disease, 
and less than 140/90 mmHg for all others;10 low density lipoprotein cholesterol (LDL) level less 
than 2.0 mmol/L if FRS was 20% or greater or if a coronary risk equivalent was present, or less 
than 3.5 mmol/L for all others8; a total cholesterol:high density lipoprotein (HDL) cholesterol 
ratio of less than 4.0 if FRS was 20% or greater or if a coronary risk equivalent was present, and 
less than 5.0 for all others;8 and an A1c of 7.0% or less for patients with diabetes.9  These goals 
were documented in the medical records of patients in the follow-up group only.  When any of 
these risk factors were uncontrolled, the pharmacist alerted the patient through phone and/or 
mail, while the physician was notified through the patient chart and in-person when possible.  
Also, the pharmacist documented the change required to reach the clinical target in the patient’s 
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medical record.  No specific recommendations regarding pharmacotherapy were given unless 
requested.   
 
Patients in the follow-up group received continuous follow-up by the pharmacist at a minimum 
of every 8 weeks by telephone, mail, electronic mail, or face-to-face appointments.  These 
regular contacts were intended to provide ample opportunities for subjects to ask questions, 
discuss laboratory results, or convey messages to the clinic staff.  Mailed letters were reserved 
for patients who were successfully controlled or had been recently contacted. Information 
delivered during follow-ups was patient specific and did not require that a standard content be 
covered. Although potential reasons for subject follow-up were suggested (Table 2.1), specific 
study algorithms or protocols were not used.  Emphasis was placed on conducting short follow-
up contacts that reminded and reinforced the importance of adherence and clinical targets. All 
subjects were followed for a minimum of 6 months. 
 
Post-Hoc Analysis  
In an effort to evaluate the extent to which study patients compared to actual usual care (i.e. 
patientss with no study involvement), a post-hoc analysis was conducted.  Briefly, the medical 
clinic maintains a roster of patients with a diagnosis of coronary artery disease.  From this list, 
156 patients who had at least one visit with their physician during the study period and had 
recorded clinical values (e.g. systolic and diastolic blood pressure, total cholesterol, LDL-
cholesterol, HDL-cholesterol, total cholesterol:HDL-cholesterol ratio, and A1c,) were randomly 
selected by the study pharmacist using a computer-generated list of random numbers between 1 
and 1000.  The study pharmacist then collected and analyzed baseline and follow-up data for the 
same time period as the original two study groups.  Ethics approval for this post-hoc analysis 
was obtained from the University of Saskatchewan Biomedical Ethics Board. 
 
Outcome Measures 
The primary endpoint was the mean reduction in global cardiovascular risk status as measured by 
the Framingham risk score.8  Secondary endpoints included individual modifiable CVD risk 
factors (systolic and diastolic blood pressure, total cholesterol, LDL-cholesterol, HDL-
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cholesterol, total cholesterol:HDL ratio, triglycerides, and A1c in those with diabetes) statin 
utilization, initiation, and adherence rates.   
 
Statin drugs were chosen as a proxy for overall drug utilization and adherence because they are 
generally indicated in most high-risk patients.8  Also, their use can be more easily tracked in an 
aggregate analysis than antihypertensive medications, which can often be appropriately switched 
or combined depending upon individual circumstances. For our analyses, statin utilization and 
adherence were based on prescription dispensations (fills) as recorded by the Saskatchewan 
Pharmaceutical Information Program database. To be classified as using a statin at the end of the 
study period, a patient must have filled at least one statin prescription during the study period, 
and have filled at least one statin prescription within 3 months after the completion of the study 
(between January 1, 2008 – March 31, 2008).  Overall statin utilization was defined as the 
number of patients who filled at least one prescription during the observation period.  Patient 
adherence to statin therapy was evaluated using the previously validated proportion of days 
covered (PDC)12, 13 – that is, the sum of the days’ supply for all statin prescription fills during the 
study period, divided by the number of days between the index date (first statin fill within the 
study period) and the end of the study period (December 31, 2007).  Only those patients who 
filled their first statin prescription at least three months before the end of the study period were 
included in the adherence analysis.   
 
Statistical Analysis 
Baseline characteristics and study results were compared using chi-square, independent t-tests, 
and analysis of variance (ANOVA), as appropriate.  Before-after mean reductions in FRS were 
evaluated using paired t-tests. All analyses were conducted using intention-to-treat. For patients 
lost to follow-up, the group mean was inputted for the missing data to facilitate the intention to 
treat analysis. For patients who had missing laboratory data at the end of the study period (e.g. 
laboratory tests not ordered or completed), the last reported results were used, provided that the 
tests occurred at least six months after randomization.  As a sensitivity analysis, we also used a 
last-observation-carried-forward approach by using baseline values.  For analyses that included 
the post-hoc control group, mean reductions in FRS were performed using analysis of covariance 
(ANCOVA); logistic regression was used for the proportion of patients exhibiting adherence 
17 
 
 
 
≥80%, and statin utilization. All analyses involving the post-hoc control group were adjusted for 
age, sex, smoking status, and length of time in study.  
 
We estimated that 77 patients would be required in each arm of the study in order to detect a 
difference of 2 points in the mean FRS between groups, assuming a one-tailed alpha of 0.05 and 
a beta of 0.80.  This effect size  [2 (SD 5) point difference] was based on an unpublished clinical 
intervention previously conducted by the primary investigator (CE), and is comparable to the 
35% expected reduction estimate used in the Steno-2 study.14  A one-tailed alpha was chosen 
because our intent with this pilot study was to maximize the sensitivity to detect a positive 
benefit of our intervention with a reasonable sample size.15  Analyses were carried out using 
SPSS version 16.0 for Windows (SPSS Inc, Chicago, Ill). 
 
2.4 Results 
A total of 252 patients were screened with 176 subsequently randomized to single contact or 
pharmacist follow-up (Figure 2.1).  Mean age of study patients was 60 years and 81% were male.  
Twenty-one percent of patients had a history of myocardial infarction, 68% had diabetes 
mellitus.  Mean blood pressure was 137/81mmHg and mean LDL-cholesterol was 2.84mmol/L. 
Overall, the mean duration of follow-up was 380 days (median 392 days) (Table 2.2).  
 
All study patients from both groups (follow-up and single contact) met face-to-face with the 
pharmacist for the initial screening interview and education session.  This session lasted 
approximately 1 hour in most cases.  Subsequently, of 88 patients assigned to follow-up care, 77 
(87.5%) received some level of additional individualized support through telephone follow-up 
(primary method), face-to-face visits, email, personalized letters, or a combination of several 
methods; face-to-face follow-up visits were arranged for only 13 (14.8%) of these 88 patients.  
The remaining 11 patients (12.5%) received no individualized attention beyond their initial 
education and screening encounter; they received only mailed “form” letters every 2 months.  In 
four of these patients, all risk factors were controlled (blood pressure, LDL level, total 
cholesterol:HDL ratio, and A1c value [if applicable]), and no subjective concerns were 
communicated to the pharmacist.  In the other seven patients, at least one uncontrolled risk factor 
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was identified; however, four of these patients did not respond to repeated attempts to contact 
them, and three were missed in the follow-up period for reasons unknown. 
 
The primary outcome of mean reduction in FRS was not significantly different between the 
follow-up and single contact groups (-2.68 and -1.25, respectively, one-tailed P=0.098) (Table 
2.3). Similarly, none of the individual secondary endpoints (systolic and diastolic blood pressure, 
total cholesterol, LDL-cholesterol, HDL-cholesterol, total cholesterol/HDL-cholesterol ratio, 
A1c) were influenced by the pharmacist intervention at the end of the follow up period (Table 
2.3).  Moreover, for patients utilizing statin therapy, mean statin adherence over the study period 
was extremely high in both groups: 90.4% (95% CI 83.9% -97.0%) in the follow-up group, and 
91.8% (95% CI 85.3% - 98.2%) in the single contact group (P=0.781).  The proportion of 
patients exhibiting adherence ≥80% was 73.1% [57/78] versus 80.0% [52/65] respectively, 
P=0.333) (Table 2.4).   
 
Before-after comparisons of the FRS within the individual study groups showed a significant 
reduction in the follow-up group (-2.68, P<0.001) but not in the single contact group (-1.25, 
P=0.134).  More patients in the follow-up group remained on statin therapy at the end of the 
study period compared to the single contact group (75/88 [85.2%] versus 59/88 [67.0%], 
respectively, P=0.005).  Also, statins appeared to be initiated more frequently in the follow-up 
group compared to the single contact group (75.0% [30/40] and 48.9% [22/45], respectively, 
P=0.013) (Table 2.4).   
 
In the post-hoc analysis, the control group (no study involvement) was slightly older, had a lower 
baseline FRS, and a lower proportion of smokers and males (Table 2.2). Clinical endpoints 
among these non-study subjects were comparable to subjects in the 2 study groups (FRS, systolic 
and diastolic blood pressure, total cholesterol, LDL-cholesterol, HDL-cholesterol, total 
cholesterol:HDL-cholesterol ratio, A1c, and adherence) (Table 2.3 and Table 2.4). Although the 
change in FRS was numerically higher in the follow up group (-2.68) compared to the single 
contact group (-1.25) and the post-hoc control group (-0.69) during the same time period, 
adjustment for prominent baseline differences (age, sex, baseline FRS, smoking status, and 
length of time in the study) eliminated the statistical significance upon comparing all three 
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groups (p=0.403, data not shown).  However, the proportion of patients filling at least one statin 
prescription after the study observation period was significantly higher in the follow-up group 
(75/88 [85.2%]) compared to the natural control group (98/156 [62.8%]).  This difference 
persisted after adjusting for age, sex, baseline FRS, smoking status, and length of time in the 
study (OR 3.31, 95% CI 1.55 – 7.07, P=0.002, data not shown). Also, new statin initiations were 
significantly more frequent among patients enrolled in the clinical study (follow-up group 30/40 
[75.0%], OR 7.28, 95% CI 2.54 – 20.93, P<0.001, and single contact group 22/45 [48.9%], OR 
3.14, 95% CI 1.30 – 7.59, P=0.011) compared to the post-hoc control cohort (14/65 [21.5%]) 
(Table 2.3), after adjusting for age, sex, baseline FRS, smoking status, and length of time in the 
study (data not shown). 
 
2.5 Discussion  
We conducted a prospective, randomized controlled study evaluating the involvement of non-
specialist pharmacist in providing collaborative cardiovascular risk care compared to usual care.  
At the end of the observation period, our primary endpoint of change in FRS was not 
significantly different between the two study groups. With respect to our secondary endpoints, 
no between-group differences were detected for any of the endpoints assessed (systolic and 
diastolic blood pressure, total cholesterol, LDL-cholesterol, HDL-cholesterol, total 
cholesterol:HDL, or A1c levels); however, many study patients exhibited controlled risk factors 
at the baseline assessment.  Furthermore, both mean adherence and the proportion of patients 
with adherence ≥80% were not improved by repeated contact with the study pharmacist.  It 
would seem that our simple hypothesis of communicating uncontrolled risk factor levels was 
either inadequate, or the study period was too brief to influence these endpoints.   
 
In contrast, we did find evidence suggesting that the pharmacist intervention significantly 
improved statin medication utilization.  Compared to the non-study post-hoc control patients, a 
higher proportion of the follow-up group were newly initiated on a statin medication and 
continued to fill a statin medication after the completion of the study period.  Overall adherence 
to statin medications was very high in all groups examined suggesting that this increased use of 
statins could potentially translate into future lowering of cardiovascular risk.   
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Interestingly, all patients enrolled in the study appeared to benefit from the pharmacist 
involvement irrespective of study group assignment.  Indeed, even the single contact group 
exhibited higher rates of statin utilization compared to the non-study post-hoc control cohort of 
patients.  These improvements in the single contact group were most likely a result of 
contamination because each physician in our study managed patients in both the follow-up as 
well as the single contact group.  It was unavoidable that the single-contact group would receive 
some benefits as a result of the communication to physicians about their follow-up counterparts.  
In our view, these findings are important for two reasons.  First, our simple pharmacist 
intervention was associated with objective benefits despite the potential for contamination that 
favoured a null finding.  Second, the benefits observed in the single contact group provide 
additional evidence for the benefits of reminding physicians about uncontrolled cardiovascular 
risk factors.  Not only did our reminders benefit the intervention group, but they appeared to 
benefit other similar patients under the physician’s care as well.  Consequently, we believe 
pharmacists who have not yet developed the skills or gained the experience in providing 
pharmacotherapeutic recommendations can still contribute to the care of patients in a 
collaborative care setting.   
 
Limitations 
Given that this was a pilot study, our sample was relatively small, only involved a single center, 
and the follow-up period was limited.  Also, none of the participants were blinded to the 
treatment assignment.  Clinical endpoints such as blood pressure were not standardized and were 
simply recorded from the medical chart.  In addition, twenty patients were lost to follow-up and 
did not have data available for analysis of the primary endpoint or secondary clinical endpoints. 
However, all data were analyzed as intent-to-treat, and we were able to evaluate all study 
patients for the statin utilization and adherence analyses.  Our primary endpoint, the FRS, is 
validated only in primary prevention populations whereas secondary prevention patients were 
also enrolled in our study.  Nevertheless, assessing global risk is considered superior to 
measuring single risk factors in both primary and secondary prevention populations,17, 18 and we 
used the FRS as a composite measure of changes in risk factors, rather than for risk prediction.  
Finally, the study was comprised of a single intervention pharmacist so we cannot definitively 
generalize our findings to all non-specialist pharmacists.  However, simple reminders systems 
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may benefit patient care in a similar manner, and we suspect the benefits of involving 
pharmacists would only increase over time.  Obviously, a larger, multi-site trial would be needed 
to confirm any benefits of this strategy.   
 
Despite these limitations, this is still one of the largest studies to date evaluating the impact of 
pharmacist involvement on cardiovascular risk reduction,3, 7, 19 and one of the few that evaluated 
a practical pharmacist intervention that could likely be carried out by non-specialist pharmacists 
in typical (i.e. fee-for-service) practice settings.  The study focused on simple, frequent contacts 
with patients and enrolled all high-risk subjects rather than just evaluating those with 
uncontrolled risk factors.  Also, we utilized a global cardiovascular measure as opposed to a 
single risk factor, which would appear to be a more practical endpoint from the perspective of 
cardiovascular risk reduction in primary care practice.   
 
2.6 Conclusion 
Although the pharmacist involvement did not result in a clear improvement to cardiovascular-
risk reduction success among patients attending a primary care medical clinic, it did result in 
apparent improvements to statin utilization.  Considering the wealth of non-specialist 
pharmacists practicing in Canada and the United States, we believe that researchers should 
continue to explore potential collaborative care roles that do not involve complex pharmaceutical 
care models.  Ultimately, such a protocol could be much more generalizable to many front-line 
pharmacists and may even result in additional opportunities for collaborative practice.    
 
 
 
 
 
22 
 
 
 
23 
Follow-up 
(n=88) 
 Single Contact 
(n=88) 
Analyzed 
(n=88) 
Analyzed 
(n=88) 
Lost to follow-up (n=9) 
 
   -Laboratory data not available (n=8) 
    -Withdrew for unrelated illness (n=1) 
Randomized 
(n=176) 
Post-Hoc Control Patients  
(n=156) 
Analyzed  
(n=156) 
Referred by Physician 
(n=252) 
Excluded (n=76) 
 
   -Did not meet inclusion criteria (n=1) 
   -Refused to participate  (n=23) 
   -Unable to arrange initial visit (n=52) 
Lost to follow-up (n=11) 
 
   -Laboratory data not available (n=9) 
    -Moved (n=1) 
    -Died (cause unknown) (n=1) 
Figure 2. 1. Flow of Study Patients  
 
 
 
Table 2.1. Potential Reasons for Pharmacist Follow-up with Patients 
 
 
 Communication of relevant laboratory results, including proximity to individual targets 
 Within 7-10 days after the initiation or change of medication 
 Within 7-10 days after experiencing an adverse event 
 To ensure patient was able to procure necessary follow-up appointments 
 Periodic mail outs providing patients with clinical goal reminders, disease specific 
information, or timely topics 
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Table 2.2. Patient Baseline Characteristics  
 
 
   Follow-Up Single  Post-Hoc P-valuea P-valueb 
     Contact  Control 
 
   n=88  n=88  n=156 
 
Characteristic    
 
Age (SD)  60.3 (10.05) 60.2 (10.19) 63.9 (12.42)  0.953  0.013 
(years) 
 
Male sex (%)  73 (83.0) 69 (78.4) 88 (56.4) 0.445c  <0.001d 
 
Cigarette Smoker (%) 21 (23.9) 13 (14.8) 8 (5.1)  0.127c  <0.001d 
 
Cardiovascular    
History 
   Post-MI (%)  19 (21.6) 18 (20.5) 43 (27.6) 0.853c  0.374d 
   Post-CVA (%)  4 (4.5)  4 (4.5)  5 (3.2)  1.000c  0.821d 
   CAD (%)  13 (14.8) 9 (10.2)  34 (21.8) 0.362c  0.057d 
 
Diabetes (%)  60 (68.2) 59 (67.0) 103 (66.0) 0.872c  0.942d 
 
FRS    16.7  15.0  12.4  0.276  0.003 
(%) 
 
Systolic BP  136.4  136.9  135.1  0.819  0.605 
(mmHg) 
 
Diastolic BP  80.0  81.3  80.0  0.332  0.503 
(mmHg) 
 
Total Cholesterol  4.85  4.67  4.54  0.349  0.142 
(mmol/L) 
 
LDL   2.88  2.79  2.68  0.605  0.340 
(mmol/L) 
 
HDL   1.13  1.16  1.15  0.548  0.832 
(mmol/L) 
 
TC:HDL  4.49  4.24  4.19  0.211  0.223 
 
Triglycerides  2.03  1.81  1.83  0.196  0.344 
(mmol/L) 
 
A1c   7.3e  7.0f  7.5g  0.200  0.064 
(%) 
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  Follow-Up Single  Post-Hoc p-valuea  p-valueb 
     Contact  Control 
 
   n=88  n=88  n=156 
 
Characteristic    
 
Drug Utilization (%) 
   Statin   48 (54.5) 43 (48.9) 91 (58.3)h 0.451c  0.360d 
   ACEI   70 (79.5) 62 (70.5)   0.164c 
   Beta Blocker  28 (31.8) 26 (29.5)   0.744c 
   ASA (or other  68 (77.3) 70 (79.5)   0.714c 
   anticoagulant/ 
   antiplatelet) 
 
a Independent t-test comparing Follow-up and Single Contact (unless indicated) 
b ANOVA test comparing Follow-up, Single Contact and Post-Hoc Control (unless indicated) 
c  Pearson’s chi-square comparing Follow-up and Single Contact 
d  Pearson’s chi-square comparing Follow-up, Single Contact and Post-Hoc Control 
e  n=54       
f n=59       
g  n=100  
h  Only statin utilization was captured for the Post-Hoc Control group    
A1c  Glycosolated haemoglobin A1c 
ACEI  Angiotensin converting enzyme inhibitor  
ASA  Acetylsalicylic acid 
BP  Blood pressure            
CAD  Coronary artery disease  
CVA  Cerebrovascular accident        
FRS  Framingham risk score (% 10-year risk)                    
HDL  High density lipoprotein  
LDL      Low density lipoprotein 
MI        Myocardial infarction 
TC:HDL Total cholesterol:high density lipoprotein  
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Table 2.3. Results at Study End 
 
   Follow-Up Single   Post-Hoc P-valuea P-valueb 
     Contact  Control  
 
   n=88  n=88  n=156 
 
Characteristic 
 
FRS   14.0  13.7  11.7  0.844  0.071 
(%) 
 
Mean Reduction in FRS 2.68  1.25  0.69  0.098  0.043 
(%)                  (one-tailed)           
 
Systolic BP  133.3  135.3  135.5  0.304  0.532 
(mmHg) 
 
Diastolic BP  76.6  77.1  79.1  0.704  0.136 
(mmHg) 
 
Total Cholesterol  4.22  4.21  4.32  0.949  0.668 
(mmol/L)  
 
LDL   2.33  2.33  2.40  0.992  0.791 
(mmol/L) 
 
HDL   1.15  1.13  1.18  0.544  0.549  
(mmol/L) 
 
TC:HDL  3.82  3.90  3.88  0.614  0.887 
 
Triglycerides  1.91  1.95  1.78  0.835  0.490 
(mmol/L) 
 
A1c   7.2c  6.9d  7.4e  0.150  0.043 
(%) 
 
Mean days in study 394  390  367  0.695  0.050 
 
a  Independent t-test comparing Follow-up and Single Contact  
b  ANOVA test comparing Follow-up, Single Contact and Post-Hoc Control  
c  n=54    
d  n=58     
e  n=100  
A1c  Glycosolated haemoglobin A1c 
BP         Blood pressure       
FRS  Framingham risk score (% 10-year risk)  
HDL  High density lipoprotein     
LDL  Low density lipoprotein 
TC:HDL Total cholesterol:high density lipoprotein  
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Table 2.4. Statin Utilization and Adherence 
 
Measure      Statin Utilization  
 
   Follow-Up Single  Post-Hoc P-valuea P-valueb 
     Contact  Control 
 
   n=88  n=88  n=156 
 
At least one statin  78 (88.6) 65 (73.9) 105 (67.3) 0.012  0.001 
fill during study period 
(%) 
 
Statin utilization at 75 (85.2) 59 (67.0) 98 (62.8) 0.005  0.001 
study end (%) 
 
New statin initiations (%) 30/40 (75.0) 22/45 (48.9) 14/65 (21.5) 0.013  <0.001 
 
 
       Statin Adherence  
 
   Follow-Up Single  Post-Hoc P-valuea P-valueb 
     Contact  Control  
 
   n=78  n=65  n=105  
 
Mean adherence (%) 90.4  91.8  92.1  0.781c  0.749d 
(95% CI)  (83.9-97.0) (85.3-98.2) (88.7-98.7) 
 
Patients adherent ≥80% 57 (73.1) 52 (80.0) 81 (77.1) 0.333  0.614 
(%) 
 
 
a  Pearson’s chi-square comparing Follow-up and Single Contact 
b  Pearson’s chi-square comparing Follow-up, Single Contact and Post-Hoc Control 
c  Independent t-test comparing Follow-up and Single Contact 
d  ANOVA test comparing Follow-up, Single Contact and Post-Hoc Control 
 
28 
 
 
 
2.7 References 
 
1. Public Health Agency of Canada. Cardiovascular Diseases - Heart Disease and Stroke.  
http://www.phac-aspc.gc.ca/cd-mc/cvd-mcv/cvd_mortality-mcv_mortalite-eng.php. 
Accessed August 18, 2009. 
2. Rabinowitz I, Tamir A. The SaM (Screening and Monitoring) approach to cardiovascular 
risk-reduction in primary care -- cyclic monitoring and individual treatment of patients at 
cardiovascular risk using the electronic medical record. Eur J Cardiovasc Prev Rehabil. 
2005;12:56-62. 
3. Geber J, Parra D, Beckey N, Korman L. Optimizing drug therapy in patients with 
cardiovascular disease: the impact of pharmacist-managed pharmacotherapy clinics in a 
primary care setting. Pharmacotherapy. 2002;22:738-747. 
4. Carter B, Zillich A, Elliot W. How pharmacists can assist physicians with controlling 
blood pressure. J Clin Hypertens. 2003;5:31-37. 
5. Tsuyuki R, Johnson J, Teo K, et al. A randomized trial of the effect of community 
pharmacist intervention on cholesterol risk management: the study of cardiovascular risk 
intervention by pharmacists (SCRIP). Arch Intern Med. 2002;162:1149-1155. 
6. Blackburn D, Evans C, Lamb D, Taylor J, Skilton K. Cardiovascular risk reduction 
strategies in community pharmacy settings need real world angle. Canadian Pharmacists 
Journal. 2007;140:295-297. 
7. Carter B, Bergus G, Dawson J, et al. A cluster-randomized trial to evaluate 
physician/pharmacist collaboration to improve blood pressure control. J Clin Hypertens. 
2008;10:260-271. 
8. McPherson R, Frohlich J, Fodor G, Genest J. Canadian Cardiovascular Society position 
statement - recommendations for the diagnosis and treatment of dyslipidemia and 
prevention of cardiovascular disease. Can J Cardiol. 2006;22:913-927. 
9. Canadian Diabetes Association. 2003 Clinical practice guidelines for the prevention and 
management of diabetes in Canada - targets for glycemic control. Can J of Diabetes. 
2003;27:S18-20. 
 
29 
 
 
 
10. Hemmelgarn B, McAlister F, Grover S, et al. The 2006 Canadian Hypertension 
Education Program recommendations for the management of hypertension: Part I--Blood 
pressure measurement, diagnosis and assessment of risk. Can J Cardiol. 2006;22:573-
581. 
11. Khan N, McAlister F, Rabkin S, et al. The 2006 Canadian Hypertension Education 
Program recommendations for the management of hypertension: Part II - Therapy. Can J 
Cardiol. 2006;22:583-593. 
12. Benner J, Glynn R, Mogun H, Neumann P, Weinstein M, Avorn J. Long-term persistence 
in use of statin therapy in elderly patients. JAMA. 2002;288:455-461. 
13. Wei L, Wang J, Thompson P, Wong S, Struthers A, MacDonald T. Adherence to statin 
treatment and readmission of patients after myocardial infarction: a six year follow up 
study. Heart. 2002;88:229-233. 
14. Gaede P, Vedel P, Larsen N, Jensen G, Parving H-H, Pederson O. Multifactorial 
intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 
2003;348:383-393. 
15. Browner W, Newman T, Cummings S, Hulley S. Getting ready to estimate sample size: 
hypotheses and underlying principles. In: Hulley S, Cummings S, eds. Designing Clinical 
Research Baltimore: Williams & Wilkins; 1988:128-138. 
16. Brookhart A, Patrick A, Schneeweiss S, et al. Physician follow-up and provider 
continuity are associated with long-term medication adherence. Arch Intern Med. 
2007;167:847-852. 
17. Grundy S, Pasternak R, Greenland P, Smith S, Fuster V. Assessment of cardiovascular 
risk by use of multiple-risk-factor assessment equations. A statement for healthcare 
professionals from the American Hearth Association and the American College of 
Cardiology. Circulation. 1999;100:1481-1492. 
18. Lear S, Ignaszewski A, Linden W, et al. A randomized controlled trial of an extensive 
lifestyle management intervention (EMLI) following cardiac rehabilitation: study design 
and baseline data. Current Controlled Trials in Cardiovascular Medicine. 2002;3:9-22. 
19. Bozovich M, Rubino C, Edmunds J. Effect of a clinical pharmacist-managed lipid clinic 
on achieving National Cholesterol Education Program low-density lipoprotein goals. 
Pharmacotherapy. 2000;20:1375-1383.
30 
 
 
 
 
 
Appendix A. Patient Education Booklet 
 
 
 
31 
 
 
 
 
 
 
 
 
 
 
32 
 
 
 
 
 
 
 
 
 
 
33 
 
 
 
 
 
 
 
34 
 
 
 
- Chapter 3 - 
DIABETES AND CARDIOVASCULAR DISEASE INTERVENTIONS BY 
COMMUNITY PHARMACISTS: A SYSTEMATIC REVIEW 
 
3.1 Abstract 
 
Objective: To systematically review and summarize community pharmacist interventions for 
preventing or managing diabetes or cardiovascular disease and/or its major risk factors.  
 
Data Sources:  A comprehensive literature search was performed using Medline, Embase, 
International Pharmaceutical Abstracts (IPA), Cumulative Index to Nursing and Allied Health 
Literature (CINAHL), and Cochrane Central Register of Controlled Trials.  The “grey” literature 
was searched using the ProQuest Dissertations and Theses, Theses Canada, and OAlster 
databases.  
 
Study Selection:  Articles published in English or French and with any study design were 
considered for the review.  Studies were included if they contained interventions designed to 
reduce the incidence, risk, or mortality of cardiovascular (CVD) or diabetes; affect clinical 
indicators of CVD or diabetes mellitus (including hypertension, dyslipidemia, or A1c); and/or 
improve adherence to treatment strategies.  Only those studies involving interventions carried out 
primarily by pharmacists in community pharmacy settings were included.  Study quality was 
assessed using a checklist validated for both randomized and non-randomized studies. 
 
Data Synthesis:  A total of 3361 studies were initially identified with 37 meeting our inclusion 
criteria.  Ten studies were randomized controlled trials, 4 were cluster randomized trials, and 2 
studies had randomized before-after designs.  The remaining studies were controlled before-after 
(n=2), cohort (n=3), and uncontrolled before-after (n=16).  Interventions focused on diabetes 
(n=11), hypertension (n=8), medication adherence (n=8), lipids (n=5), evidence based 
medication initiation or optimization (n=3), risk factor prediction scores (n=1), and body mass 
index (n=1).  All studies contained interventions focused at the patient level and the majority of 
studies (32/37) involved interventions directed at both the physician and patient.  No specific 
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intervention(s) emerged as being superior, and study quality was generally poor, making it 
difficult to determine the true effect of the intervention(s). 
 
Conclusions:   The majority of community pharmacy studies reviewed appeared to show benefit 
in the reduction or management of diabetes or CVD.  However, poor study quality, time-
intensive interventions, and unproven clinical significance warrant the need for further high 
quality studies.  
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3.2 Introduction 
Community pharmacists have been involved in activities related to the prevention and 
management of cardiovascular disease (CVD) and diabetes for many years, with research dating 
back to the late 1970’s.  Over the past decade, the number of community pharmacy practice 
publications has increased substantially.  This increase is likely driven by several factors: 
recommendations that pharmacists should play a more active role in disease management1-6, a 
push from within the profession to broaden the role of community pharmacists beyond the 
traditional dispensing and distribution functions7, and an increasing need to generate objective 
evidence supporting these expanded roles.   
 
There have been numerous studies reporting clinically significant benefits of community 
pharmacist interventions in diabetes and CVD.  Some would argue, however that major 
advancements in real-world practice have not followed suit.8  It has been suggested that this may 
be due to a lack of knowledge synthesis (e.g. systematic reviews) or ineffective dissemination of 
the results.8  It is also possible that the published pharmacy research used as evidence for 
practice change has lacked the quality and/or generalizability necessary to successfully guide and 
support this change.   
 
Although previous reviews have looked at community pharmacist interventions involving CVD 
or diabetes, they had a limited search strategy,5, 9-11 were focused on a single risk factor,5, 9, 11, 12 
were not specific to community pharmacists (e.g. hospital or clinic-based),5, 10, 11, 13 or are now 
dated.14  Thus, we aimed to systematically review and summarize community pharmacist 
interventions directed at the prevention or management of diabetes or CVD and/or their major 
risk factors.  
 
3.3 Methods 
Search Strategy  
A comprehensive literature search was performed by a librarian (EW) using the databases 
Medline (1950-), Embase (1980-), International Pharmaceutical Abstracts (IPA) (1970-) and 
Cochrane Central Register of Controlled Trials (1898-) from date indicated to November 2009 
(Appendix B). Searches were initially carried out in June 2007 and then re-run to find additional, 
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new articles in December 2007.   Database e-mail alerts from Medline, Embase, and IPA were 
used to notify the authors of any articles published after December 2007; these alerts were 
monitored until the end of November 2009.  In addition, the Cumulative Index to Nursing and 
Allied Health Literature [CINAHL (1982-)] was also searched initially; however, partway 
through the project, the database provider changed, limiting search access and therefore  it was 
not included after June 2007.  The “grey” literature was searched using the ProQuest 
Dissertations and Theses, Theses Canada, and OAlster databases; searches were done in August 
2009.  Systematic review articles and bibliographies from original studies were also hand 
searched for potentially relevant studies; experts and/or authors were not contacted.  No 
publication date limits were used in the searches. 
 
Inclusion and Exclusion Criteria 
To maximize the inventory of pharmacy-practice interventions that have been evaluated over the 
years, all studies published in English or French were considered for the review without regard 
for study design.  However, only full text articles were included.  Interventions must have been 
intended to reduce the incidence, risk, or mortality of CVD or diabetes; affect clinical indicators 
of CVD or diabetes mellitus (including hypertension, dyslipidemia, body weight, or A1c); and/or 
improve adherence to cardiovascular or diabetes therapies.  Only those studies involving 
interventions carried out by pharmacists in community pharmacy settings were included.  
Interventions that focused solely on patient screening, and those that did not report measured 
outcomes, were excluded.   
 
Review Methods 
All duplicate records were removed electronically (RefWorks software) and the remaining 
identified abstracts were screened by the reviewers (CE, DB, EW, DL) to assess their eligibility.  
Full copies of the potentially eligible studies were obtained, and each study was reviewed 
independently by 2 of 4 possible reviewers (CE, DB, EW, DL) to determine whether they should 
be included.  Studies were evenly distributed between the 4 reviewers.  Discrepancies were 
resolved by one of the reviewers who was not involved in the original review.  Data was initially 
extracted by 2 of 4 possible reviewers (CE, DB, EW, DL), and included author, year of 
publication, study design, patient population, sample size, study outcomes, intervention(s), 
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length of intervention(s) and results.  Results specific to the primary outcome, and conclusions 
made by the authors were further extracted by CE.  If a primary outcome was not specified, the 
first outcome reported in the results section was used unless another outcome was specified in a 
power calculation. 
 
Methodological quality of the selected studies was assessed independently by two authors (CE, 
EY) using a quality checklist validated for both randomized and non-randomized studies.15  Only 
studies with a control group were scored, as uncontrolled studies are already known to be of low 
quality.16, 17  The maximum score on the checklist is 32, and those studies with a score of less 
than 18 were considered to be of low quality.18  Any scoring discrepancies were resolved by a 
third author (DB).  Given the disparity of the studies, a meta analysis was not performed.   
 
3.4 Results 
Our search initially resulted in 3361 citations, and 37 studies met the inclusion criteria (Figure 
3.1).  Inter-observer agreement was κ=0.8753 for study inclusion among reviewers, indicating 
excellent agreement. Ten studies were randomized controlled trials (RCTs), 4 were cluster 
randomized (randomized by community pharmacy or district rather than individual subjects).  
Two studies19, 20 that were labelled by the authors as RCTs have been categorized as a 
randomized before-after design, given the fact that no between-group comparisons were made.  
In each of the four cluster randomized studies identified, the authors inappropriately failed to 
account for the clustering effect in the analyses.21, 22  The remaining studies were cohort (n=3), 
controlled before-after (n=2), and uncontrolled before-after (n=16).    
 
Studies were published between 1978 and 2009, with the majority published after 1999 (Table 
3.1).  Based on the primary endpoint, interventions focused on diabetes (n=11),23-34 hypertension 
(n=8),20, 35-41 medication adherence (n=8),42-49 and lipids (n=5).19, 50, 51  The remaining studies 
focused on evidence based medication initiation or optimization (n=3),52-57 risk factor prediction 
scores (n=1),58 and body mass index (n=1).59 Study lengths were variable and ranged from 2 to 
57 months.  
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Interventions 
Based on the descriptions provided by the authors, interventions were classified as either patient-
directed (pharmacist activities directed primarily towards patients) or physician-directed 
(pharmacist activities directed primarily towards physicians) (Table 3.2).  All studies contained 
interventions involving patients and the majority of studies (32/37) involved interventions 
directed at both the physician and patient.  Overall, we found few differences between the types 
of interventions tested in the last decade compared to those in the 1970’s and 1980’s (Figure 
3.2). 
 
Patient-directed interventions were most commonly in the form of regular follow-up (35/37 
[94.6%]) or education (35/37 [94.6%]), with only a few using reminders (e.g. reminders to refill 
prescriptions) (4/37 [10.8%]).  Education was provided by the pharmacist either verbally or 
through written materials, and typically included information relating to the patient’s disease 
state and medications (e.g. mechanism of action, adverse effects).  Appropriate lifestyle 
management (diet, exercise, and smoking cessation) was frequently discussed, as was the 
importance of medication adherence.  Follow-ups were conducted in person, by telephone, or 
mail, and generally occurred at pre-determined intervals ranging from 2 weeks25 to 3 months.23, 
24, 32, 43, 55  However, some interventions allowed for individualized impromptu follow-ups based 
on the perceived need by either the patient or pharmacist.28, 52  Patient reminders included 
methods to remind patients to take or refill their medications, or “compliance packaging” of 
medications.47 
 
The identification of drug related problems (DRPs) and subsequent therapeutic recommendations 
was a key component of many physician-directed interventions (25/37 [67.6%]).  
Recommendations to physicians included therapy initiation, dosage adjustments, and the 
ordering of laboratory tests.  Several interventions (14/73 [37.8%]) included notifying physicians 
of their patients’ involvement in, or progress with, the study through various means (e.g. fax, 
telephone).  Finally, 8/37 (21.6%) interventions required the pharmacist to refer patients back to 
their physician for appropriate follow-up.  
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Interventions were typically time intensive, often requiring individual patient interviews, follow-
up, and extensive collaboration with physicians.  Out of 16 studies with available data, the 
median time per patient activity (typically patient interviews or consultations) was 27 minutes, 
with some lasting up to 65 minutes.49, 59  However, only three studies commented on the 
complexity of their interventions: one study reported the adjustments that had to be made to 
“accommodate the increased time commitment needed for the project”;55 one utilized 
pharmacists who were not involved in dispensing activities;33 and only one considered the 
feasibility and practical implications of implementing the intervention into community pharmacy 
practice.41 
 
Overall, favourable results were reported or concluded by the authors in 29/37 (78%) studies 
with more favourable results reported in studies without a control group [85% (17/20)] compared 
to 71% (12/17) in those with a control group (Table 1). Accurately evaluating the impact of the 
specific interventions was difficult as many authors did not specify a primary endpoint or 
incompletely reported the results.20, 30, 33, 34, 36, 46 Regardless, the 3 most commonly tested 
interventions (patient education, patient follow-up, and the identification of drug related 
problems and subsequent physician recommendations) were deemed effective in producing a 
“significant” difference in the primary outcome in the majority of the studies; however, it was 
impossible to determine whether any intervention type was superior.  While these results are 
promising, it is important to note that the authors’ favourable conclusions were not supported by 
any reported data in at least 2 of the reviewed studies.27, 48 In addition, none of the studies 
demonstrated any benefits to major health outcomes and were mainly restricted to relatively 
small differences in drug utilization, laboratory outcomes, or medication adherence.  Therefore, 
the clinical importance of these interventions remains unclear.  
 
Study Quality  
Quality scores for those studies evaluated (only those studies with a control group were assigned 
a quality score) were poor, as only 6/21 (28.6%) studies received a score of 18/32 (56%) or 
greater.15   All 6 studies were published in the last decade.  Studies published from 2004-2009 
scored relatively higher on items assessing reporting quality than did studies published before 
41 
 
 
 
2004.  In most cases, poorly reported studies lacked an adequate description and/or comparison 
of subjects at baseline, and did not report p-values (or confidence intervals) for the study results.   
 
Randomized studies scored relatively better than the non-randomized designs, as expected, but 
only six (out of 16) achieved a score of 18/32 or higher.  Of the 16 randomized design studies, 
only one study reported blinding of the personnel involved in data collection and analysis, and 
only 3 reported blinding of the intervention allocation.  Intention to treat (ITT) analysis was 
explicitly mentioned in 8/16 (46.6%) randomized studies,20, 35, 38, 42, 43, 47, 52, 54  however only 5 of 
these studies performed an appropriate ITT analysis.   
 
Overall, only 12/37 (32.4%) studies described an a priori power calculation, and only 4 of these 
actually achieved adequate power for analysis of the primary endpoint.  Identification of pre-
determined outcomes was poor, particularly in the uncontrolled before-after studies, where only 
9/16 (56.2%) of these studies clearly specified a primary endpoint.   
 
  
3.5 Discussion  
To the best of our knowledge, this is the first systematic review that has summarized 
interventions specific to community pharmacists that focus on both diabetes and CVD and all 
major related risk factors.  All identified studies involved patient-directed interventions such as 
education and follow-up.  Most studies also involved physician-directed interventions, the most 
common of which was the identification of drug related problems and provision of therapeutic 
recommendations.  The majority of studies were published in the last 10 years, although the 
interventions have remained similar over the past 30 years.  Studies were generally of poor 
quality and evaluated interventions that typically appeared to be time intensive.  
 
Poor study quality has plagued pharmacy practice research for years,60-62 and problems range 
from poor design to poor reporting.  Although RCTs are considered the gold standard for the 
evaluation of treatment efficacy/effectiveness, the majority of studies in this review used a non-
randomized design.  In fact, 16 of the studies did not use a control group at all, and 2 studies with 
a control group made no between-group comparisons.  Without a control group, it is difficult to 
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conclude a causal relationship between the intervention being evaluated and the subsequent 
outcome(s).63 
 
Based on the studies examined in this review, reporting of results seems to have improved over 
time, and is likely due to the development of guidelines for the reporting of both randomized and 
observational studies.64, 65  However, poor reporting was still an issue even in more recent 
publications especially in the non-randomized studies.  The lack of a clearly identified primary 
outcome, and appropriate statistical comparisons (i.e. p-values and confidence intervals) were 
common, and made it difficult to evaluate and interpret the results.  In some cases the authors 
suggested favourable outcomes that were either inconsistent with the results reported,27, 48 or not 
supported by statistical evidence.34, 36, 46   
 
A major challenge when designing pharmacy research is the matter of blinding.  In most cases, it 
is difficult for either the patients or study researchers to be blinded, especially if the intervention 
involves direct patient care.  However, because blinding is a factor in most quality assessment 
scores, some argue that the quality of pharmacy practice studies will always be underestimated.8  
Blinding those responsible for the data collection and analysis, and the concealment of 
intervention allocation in RCTs, can reduce bias and improve study quality; however, these 
strategies were rarely undertaken in these studies. 
 
Study quality was likely influenced by several factors.  First, contemporary techniques to 
minimize bias and confounding may have been unknown to many investigators who conducted 
their research before the 1990’s.  Indeed, we found that studies published since 2000 were 
generally of higher quality compared to all others.  Interestingly, we could not identify major 
differences in the types of interventions used in lower-quality studies versus high-quality studies.  
Similarly, we could not find any notable differences in the types of pharmacist interventions 
tested throughout the years.  For example, in 1978, McKenney et al evaluated a pharmacist 
intervention that was comparable to more recent interventions published in the pharmaceutical 
care era.         
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The majority of interventions involved in-depth consultations with individual patients (and 
subsequently physicians or other health care professionals) for the purpose of identifying and 
resolving actual and potential drug related problems.66, 67  In general, these strategies appeared to 
be time-intensive, and their impact on patient outcomes remains unproven.  Also, the extent to 
which these strategies could be integrated into current community pharmacy settings is not clear.  
Only three studies commented on the impact the intervention had on staffing and time 
requirement of employees.  Even highly successful interventions51 will have little benefit if they 
cannot be implemented in real world settings.68-71  We believe that more research is needed to 
evaluate strategies that can be implemented into current community pharmacy practice.  
 
Limitations 
A limitation of our search strategy is that we only included full text articles published in English 
or French.  Although 5 studies were excluded based on language, it is unlikely that the 
intervention(s) being evaluated in those studies differed significantly from the included studies.  
Categorization of interventions and quality assessments were based on what was reported in the 
published studies, and we did not contact authors for extra details.  As with any systematic 
review, there is the potential for publication bias.  The quality checklist used has its own 
limitations.  The lack of a reference standard for the total quality score forces reviewers to make 
a judgement call on what they consider to be an acceptable level of quality.72  We chose a score 
of 18/32 or higher based on a previously published review,18 although much lower acceptable 
levels of quality have also been used.72  The checklist also required subjective judgements which 
were often made more difficult by the poor reporting of some studies.  However, by using two 
independent reviewers and a third to resolve any discrepancies, we can have confidence in our 
assessments.   
 
3.6 Conclusion 
The majority of community pharmacy studies reviewed from the past 30 years appear to show 
benefit in the reduction, or management, of diabetes or CVD and its risk factors.  However, study 
quality was generally poor, interventions were time intensive, and none of the studies 
demonstrated any benefits to major health outcomes.  Therefore, the clinical importance of these 
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interventions remains unclear, and further well-designed, well-conducted studies are needed to 
guide community pharmacists in this important area of practice. 
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Figure 3.1. Diagram of Literature Search  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Potentially relevant publications identified from 
databases  
(n=3361) 
Abstract screened 
(n=2840) 
Potentially eligible studies 
(n=158) 
Duplicate records removed (n=521) 
Eligible studies for inclusion 
(n=37) 
Excluded because: 
   -Not community pharmacy specific (n=19) 
   -Not cardiovascular or diabetes specific (n=13) 
   -No clinical outcomes reported (n=38) 
   -Primary focus on screening (n=8) 
   -Interdisciplinary (n=7) 
   -Language other than English or French (n=5) 
   -Abstract only available (n=8) 
   -Review/Editorial/Letter (n=19) 
   -Duplicate reporting or subgroup analysis (n=4) 
    
Excluded because not a cardiovascular or diabetes 
intervention, or did not involve community pharmacists 
(n=2682) 
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Figure 3.2. Proportion of Interventions Published by Decade  
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Patient Education - Initial education and/or counselling session provided directly to patient 
Patient Follow-up - Regular contact with patients (in-person, phone, mail) 
Patient Reminders - Medication reminders and/or compliance packaging (no patient education 
provided) 
Drug Related Problems / Recommendations - Identification of actual or potential drug related 
      problems and/or therapeutic recommendations made to physician by the pharmacist in 
     response to identified drug related problems 
Physician Notification - Physician notified about patient’s study involvement and/or progress (no specific 
     recommendations made) 
Physician Referral - Patient referred to physician by pharmacist 
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Table 3.1. Characteristics of Included Studies  
 
 
Sample Size 
 
Intervention Categoryb Author 
(year) 
Study 
Design 
Study Population 
Intervention 
 
Comparator 
Primary 
Outcomea 
Intervention Comparator 
Intervention 
Length  
Resultsc 
 
Quality 
Scored 
Doucette23 
(2009) 
RCT Type 2 diabetes 
 
n=36 
 
n=42 
 
Change in mean A1c  PT-ED  
PT-FU  
 
MD-DRP 
MD-NOT 
 
Usual care 
 
12 months Unfavourable  Low 
Nietert42 
(2009) 
 
RCT Patients at least 7 
days overdue for a 
diabetes, 
hypertension, lipid, 
depression or 
psychosis medication  
 
Phone group 
   n=1018 
 
Fax group 
   n=1016 
n=1014 Time to refill (days)  
 
Phone group 
   PT-FU 
   PT-RE 
 
Fax group 
   MD-NOT 
   (patient 
    late for 
    refills) 
 
Usual care 7 months 
 
Unfavourable High 
Planas35  
(2009) 
 
 
 
 
RCT Diabetes with 
hypertension  
 
 
n=32 n=20 Change in mean 
systolic BP  
PT-ED 
PT-FU 
 
MD-DRP 
MD-NOT 
 
Usual care 9 months  Favourable  Low 
Fera24 
(2008) 
Uncontrolled 
before-after 
 
Diabetes n=914 N/A Change in mean A1c 
from baseline 
PT-ED 
PT-FU 
 
MD-NOT 
 
N/A Minimum 3 
months 
 
Favourable  N/A 
Krass25   
(2007) 
CRT Type 2 diabetes n=28 
pharmacies 
n=28  
pharmacies 
Change in mean A1c PT-ED 
PT-FU 
 
MD-DRP 
MD-REF 
 
 
 
Usual care 6 months  Favourable Low 
Lai36 
(2007) 
Uncontrolled 
before-after 
Hypertension n=103 N/A Change in mean BP 
from baseline 
PT-ED 
PT-FU 
 
MD-DRP 
N/A 9 months Favourable  
 
N/A 
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Sample Size 
 
Intervention Categoryb 
49 
Author 
(year) 
Study 
Design 
Study Population 
Intervention 
 
Comparator 
Primary 
Outcomea 
Intervention Comparator 
Intervention 
Length  
Resultsc 
 
Quality 
Scored 
 
MEDMAN52 
(2007) 
RCT CHD  n=980 n=513 Proportion of patients 
receiving secondary 
prevention treatment 
for CHD  
 
PT-ED 
PT-FU 
 
MD-DRP 
Usual care 12 months Unfavourable High 
Semchuk53 
(2007) 
Uncontrolled 
before-after 
 
High risk for CV 
events   
 
n=217 N/A Proportion of patients 
with a dose increase 
or addition of any CV 
risk-lowering med 
compared to baseline  
 
PT-ED 
PT-FU 
 
MD-DRP 
MD-NOT 
MD-REF 
 
N/A 24 weeks Favourable  N/A 
Fornos26 
(2006) 
RCT Type 2 diabetes  
 
n=58 n=56 Change in mean A1c  
 
PT-ED 
PT-FU 
 
MD-DRP 
 
Usual care 13 months Favourable  High 
Krass27 
(2006) 
Cohort 
 
Type 2 diabetes 
 
n=39 n=79 Change in mean A1c  PT-ED 
PT-FU 
 
MD-DRP 
MD-NOT 
 
PT-ED 
 
 
 
MD-DRP 
6 months Favourable 
 
 
 
 
Low 
Oparah37 
(2006) 
 
Uncontrolled 
before-after 
 
Hypertension n=42 N/A Change in mean BP 
from baseline  
PT-ED 
PT-FU 
 
MD-DRP 
 
N/A 6 months Favourable N/A 
Vrijens43  
(2006) 
 
CRT  Patients taking 
atorvastatin for at 
least 3 months  
n=194 n=198 Proportion of days 
that the pill bottle 
(MEMS) was opened  
 
PT-ED 
PT-FU 
PT-RE 
 
 
Usual care 12 months Favourable  High 
Garrett28 
(2005) 
Uncontrolled 
before-after 
 
Diabetes  n=256 N/A Change in mean A1c 
from baseline  
 
 
 
 
 
PT-ED 
PT-FU 
 
MD-DRP 
MD-NOT 
MD-REF 
 
 
 
N/A Minimum 3 
months   
Favourable  N/A 
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Sample Size 
 
Intervention Categoryb 
50 
Author 
(year) 
Study 
Design 
Study Population 
Intervention 
 
Comparator 
Primary 
Outcomea 
Intervention Comparator 
Intervention 
Length  
Resultsc 
 
Quality 
Scored 
Paulos19 
(2005) 
Randomized 
Before-after 
Dyslipidemia   n=23 n=19 Change in mean TC 
from baseline 
 
PT-ED 
PT-FU 
 
MD-DRP 
MD-REF 
 
 
Usual care 16 weeks Favourable Low 
Taylor29 
(2005) 
 
Controlled 
Before-after 
 
Type 2 diabetes  n=128 n=111 Change in mean A1c 
from baseline 
 
PT-ED 
PT-FU 
 
 
Usual care 9 months  Favourable  Low 
Zillich38  
(2005) 
 
CRT 
 
Hypertension  n=6 
pharmacies 
n=6 
pharmacies 
Change in mean 
systolic and diastolic 
BP 
PT-ED 
PT-FU 
 
MD-DRP 
PT-FU 3 months Unfavourable 
for systolic BP 
 
Favourable for 
diastolic BP 
 
Low 
SCRIP-plus 
Tsyuyki50 
(2004) 
 
 
Yamada51 
(2005) 
Uncontrolled 
before-after 
 
Very high risk for 
CV events  
n=419 N/A Change in mean LDL 
from baseline 
 
 
 
Change in LDL one 
year after completion 
of intervention   
 
PT-ED 
PT-FU 
 
MD-DRP 
N/A 6 months  
 
 
 
 
Favourable  
 
(Maintained 12 
months after 
completion of 
intervention)  
N/A 
Ali44 
(2003) 
Uncontrolled 
before-after 
 
Non-adherent to 
cholesterol meds in 
previous 3 months  
 
n=149 N/A Change in medication 
compliance 
(prescription refill 
rate) from baseline  
 
PT-ED 
PT-FU 
 
MD-NOT 
 
 
 
N/A 6 months  Favourable  N/A 
Ashville 
Project31 
Cranor  
(2003) 
 
Cranor30 
(2003) 
Uncontrolled 
before-after 
 
 
 
 
 
 
 
 
Diabetes 
 
n=85 N/A Change in proportion 
of patients with A1c 
≤7.0% from baseline 
PT-ED 
PT-FU 
 
MD-REF 
N/A 7-9 months 
 
 
 
 
Up to 5 years 
Favourable  
 
 
 
 
 
 
 
N/A 
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Sample Size 
 
Intervention Categoryb 
51 
Author 
(year) 
Study 
Design 
Study Population 
Intervention 
 
Comparator 
Primary 
Outcomea 
Intervention Comparator 
Intervention 
Length  
Resultsc 
 
Quality 
Scored 
Bouvy45 
(2003) 
RCT Heart failure and 
taking a loop diuretic  
 
n=74 n=78 Medication non-
compliance (days 
without medication 
as identified by 
MEMS) 
 
PT-ED 
PT-FU 
 
MD-NOT 
Usual care 6 months Favourable Low 
Chabot39 
(2003) 
Cohort 
 
Hypertension  n=41 n=59 Change in mean BP  PT-ED  
(based on  
computerized 
decision aid 
tool) 
PT-FU 
 
MD-DRP 
 
Usual care 9 months Unfavourable  
 
(Only 
favourable for 
SBP in subjects 
with a high 
income) 
 
Low 
Krass59 2 
(2003) 
Uncontrolled 
before-after 
 
Not being treated for 
dyslipidemia or 
hypertension 
 
n=282 N/A Change in mean BMI 
from baseline 
PT-ED 
PT-FU 
 
MD-REF 
 
 
 
N/A 3 months  Unfavourable 
 
N/A 
Taylor46  
(2003) 
Uncontrolled 
before-after 
 
Elderly African 
Americans with 
hypertension  
n=8 N/A Change in medication  
compliance (“variant 
of tablet count”)from 
baseline  
 
PT-ED 
PT-FU 
 
MD-DRP 
 
N/A 3 months  Favourable 
 
N/A 
Garcao40 
(2002) 
RCT Hypertension  n=50 n=50 Proportion of patients 
with controlled BP 
PT-ED 
PT-FU 
 
MD-DRP 
 
 
Usual care 6 months  Favourable High 
Nau32 
(2002) 
Uncontrolled 
before-after 
 
Type 2 diabetes   n=47 N/A Change in mean A1c 
from baseline  
 
 
PT-ED 
PT-FU 
 
MD-DRP 
MD-NOT 
 
 
 
 
 
N/A 9 months 
(median) 
 
Unfavourable N/A 
51 
 
 
 
Sample Size 
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Study 
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Intervention Comparator 
Intervention 
Length  
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Quality 
Scored 
Tsuyuki54 
(2002) 
RCT High risk for CV 
events  
 
n=344 n=331 Composite: physician 
ordered fasting lipid 
panel, initiates a new 
cholesterol lowering 
drug, or increases the 
dose of a current 
cholesterol drug 
 
PT-ED 
PT-FU 
 
MD-DRP 
MD-NOT 
PT-ED 
PT-FU 
 
 
 
 
 
 
 
16 weeks Favourable High 
Blenkinsopp41 
(2000) 
CRT  
 
Hypertension  
 
n=11 
pharmacies 
n=9 
pharmacies 
Proportion of patients 
with controlled BP  
PT-ED 
PT-FU 
 
MD-DRP 
MD-REF 
 
Usual care 6 months  Favourable  Low 
Bluml55 
(2000) 
Uncontrolled 
before-after 
 
Dyslipidemia  
 
n=397 N/A Change in mean TC 
from baseline 
PT-ED 
PT-FU 
 
MD-DRP 
MD-NOT 
 
N/A 24.6 months 
(mean) 
Favourable N/A 
McMillan-
Nola58 
(2000) 
Controlled 
Before-after 
Known CAD or lipid 
levels requiring 
treatment   
 n=25 n=26 Change in risk factor 
prediction scores 
from baseline  
 
PT-ED 
PT-FU 
 
MD-DRP 
Usual care 6 months Unfavourable  Low 
Berringer33 
(1999) 
 
 
 
 
Uncontrolled 
before-after 
 
Diabetes n=82 N/A Change in mean 
SBGM  from 
baseline  
PT-ED 
PT-FU 
 
MD-DRP 
N/A 12 months Favourable 
 
N/A 
Fincham34 
(1998) 
Uncontrolled 
before-after 
 
Diabetes 
 
n=51 N/A Proportion of patients 
having a foot exam 
performed compared 
to baseline 
 
PT-ED N/A 2 months Favourable  
 
N/A 
Shibley56  
(1997) 
Uncontrolled 
before-after 
 
 
 
 
 
Hyperlipidemia  n=25 N/A Change in mean TC 
from baseline 
PT-ED 
PT-FU 
 
MD-DPR 
MD-NOT 
 
N/A 12 months Favourable N/A 
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Sample Size 
 
Intervention Categoryb 
53 
Author 
(year) 
Study 
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Study Population 
Intervention 
 
Comparator 
Primary 
Outcomea 
Intervention Comparator 
Intervention 
Length  
Resultsc 
 
Quality 
Scored 
Park20  
(1996) 
Randomized 
before-after 
Hypertension  n=32 n=32 Mean systolic  and 
diastolic BP  
PT-ED 
PT-FU 
 
MD-DRP 
 
 
 
 
Usual care 4 months  Favourable  
 
Low 
Skaer47 
(1993) 
RCT Newly diagnosed 
Type 2 diabetes 
receiving a first 
prescription for 
glyburide 5mg BID 
 
Mail 
reminder 
   n=79 
 
Compliance 
packaging 
   n=53 
 
Reminder + 
packaging 
   n=48 
 
 
n=78 Adherence (MPR) 
 
PT-RE Usual care 360 days Favourable Low 
Ibrahim57 
(1990) 
Uncontrolled 
before-after 
 
Not previously 
diagnosed with 
dyslipidemia  
n=57  N/A Change in mean TC 
from baseline 
PT-ED 
PT-FU 
 
MD-REF 
 
 
 
 
N/A 6 months  Favourable N/A 
Ascione48 
(1985) 
RCT Taking at least one 
CV medication  
n=52 n=50 Proportion of patients 
refilling prescriptions 
late 
 
PT-ED 
PT-FU 
PT-RE 
Usual care 4 months Favourable  
 
 
Low 
McKenney49 
(1978) 
Cohort 
 
Hypertension  n=70 n=66 
 
 
 
Proportion of 
compliant patients 
(receiving +/-15% of 
prescribed dose) 
 
PT-ED 
PT-FU 
 
MD-DRP 
MD-NOT 
 
Usual care 4 months  Favourable Low 
RCT Randomized controlled trial 
BP Blood pressure  
N/A Not applicable  
CRT Cluster randomized trial 
53 
 
54 
CHD Coronary heart disease 
CV Cardiovascular  
MEMS Medication event monitoring system  
TC Total cholesterol  
LDL Low density lipoprotein  
BID Twice daily  
MPR Medication possession ratio  
a.    If no primary outcome specified, we used the first outcome reported in the Results section, or outcome used in power calculation (if done). 
b.    Intervention categories: 
  PT-ED = Patient-directed education 
   PT-FU = Regular patient follow-up 
   PT-RE = Medication reminders or compliance packaging 
  MD-DRP = Identification and reporting of drug related problems and subsequent recommendations made to patient’s physician  
   MD-NOT = Notification to the physician about patient’s participation or progress in the study  
  MD-REF = Patients were referred to their physician by the pharmacist 
c.   Based on authors’ conclusions 
d.   Based on Downs and Black Checklist;15  High ≥18/32 (56%); Low <18/3218    
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Table 3.2. Categorization of Interventions 
 
Categories Description 
Patient-directed 
 
   Education 
 
 
   Follow-up 
    
   Reminders 
 
 
 
Initial education and/or counselling session provided directly to 
patient 
 
Regular contact with patients (in-person, phone, mail) 
 
Medication reminders and/or compliance packaging (no patient 
education provided) 
 
Physician-directed 
 
   Drug related problems - 
   Recommendations  
    
 
 
   Notification 
 
  
   Referral  
 
 
Identification of actual or potential drug related problems and/or 
therapeutic recommendations made to physician by the pharmacist 
in response to identified drug related problems 
 
 
Physician notified about patient’s study involvement and/or 
progress (no specific recommendations made) 
 
Patient referred to physician by pharmacist 
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Appendix B.  List of Search Terms Used  
 
The focus of this review was community pharmacy interventions, therefore in each database, a 
series of terms was used to identify articles about pharmacists, and another series of terms was 
used to identify those which took place in the community.  These were combined with AND so 
that each article would contain a term describing each of these concepts.  In databases which 
permitted use of more complicated search strategies (i.e., CINAHL, CENTRAL, EMBASE, IPA, 
and MEDLINE), additional terms were used to specify that articles include terms relating to at 
least one of hypertension, dyslipidemia, diabetes, cardiovascular disease, or adherence to drugs 
for treatment of one of the conditions listed above.   No language restrictions were applied to the 
searches. 
 
 
Wiley Cochrane Central Controlled Trials Registry (CENTRAL) 
Searched December 2007 
 
1     (pharmacist*):ti,ab,kw or (druggist*):ti,ab,kw or (chemist*):ti,ab,kw or (pharmacy):ti,ab,kw or 
(pharmacies):ti,ab,kw 
2     (drugstore*):ti,ab,kw or (pharmaceutical NEXT care):ti,ab,kw or (pharmaceutical NEXT service*):ti,ab,kw 
3     (#1 OR #2) 
4     (community):ti,ab,kw or (retail):ti,ab,kw or (chain):ti,ab,kw or (neighborhood):ti,ab,kw or 
(neighbourhood):ti,ab,kw 
5     (#4 AND #3) 
6     (hypertens*):ti,ab,kw or (blood NEXT pressure):ti,ab,kw or (systolic):ti,ab,kw or (diastolic):ti,ab,kw 
7     (cholesterol) or (hdl):ti or (ldl):au or (vldl):ab or (lipoprotein*):kw 
8     (dyslipid*em*):ti,ab,kw or (hyperlipid*em*):ti,ab,kw or (hyperlip*em*):ti,ab,kw or 
(hypercholesterol*em*):ti,ab,kw or (hypertriglycerid*em*):ti,ab,kw 
9     (hyperlipoprotein*em*):ti,ab,kw or (hypolipoprotein*em*):ti,ab,kw or (dyslipoprotein*em*):ti,ab,kw or 
(lip*em*):ti,ab,kw or (dyslip*em*):ti,ab,kw 
10     (cholesterol*em*):ti,ab,kw or (lipid*):ti,ab,kw or (lipoprotein*em*):ti,ab,kw or (triglyceride*):ti,ab,kw 
11     (#7 OR #8 OR #9 OR #10) 
12     (blood NEXT glucose):ti,ab,kw or (blood NEXT sugar):ti,ab,kw or (hyperglyc*em*):ti,ab,kw or 
(hypergluc*em*):ti,ab,kw or (glucose NEXT intoleran*):ti,ab,kw 
13     (hypoinsulin*em*):ti,ab,kw or (insulin NEXT deficien*):ti,ab,kw or (insulin NEXT dependen*):ti,ab,kw or 
(insulinop*en*):ti,ab,kw or (Insulin NEXT insufficien*):ti,ab,kw 
14     (insulin*em*):ti,ab,kw or (glycosylated NEXT hemoglobin NEXT a):ti,ab,kw or (glycosylated NEXT 
haemoglobin NEXT a):ti,ab,kw or (a1c near/1 hemoglobin):ti,ab,kw or (a1c near/1 haemoglobin):ti,ab,kw 
15    (hb NEXT a1c):ti,ab,kw or (hba1c):ti,ab,kw or (dysglyc*em*):ti,ab,kw or (dysgluc*em*):ti,ab,kw or 
(dysinsulin*em*):ti,ab,kw 
16     (insulin NEXT resistan*):ti,ab,kw or (metabolic NEXT syndrome):ti,ab,kw or (syndrome NEXT x):ti,ab,kw or 
(diabet*):ti,ab,kw or (prediabet*):ti,ab,kw 
17     (niddm):ti,ab,kw 
18     (#12 OR #13 OR #14 OR #15 OR #16 OR #17) 
19     (cardio*):ti,ab,kw or (vascular):ti,ab,kw or (heart):ti,ab,kw or (cardiac):ti,ab,kw or (coronary):ti,ab,kw 
20     (stroke):ti,ab,kw or (apople*):ti,ab,kw or (infarct*):ti,ab,kw or (brain NEXT attack*):ti,ab,kw or 
(cerebrovascular):ti,ab,kw 
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21     (thrombo*):ti,ab,kw or (embol*):ti,ab,kw or (isch*em*):ti,ab,kw or (myocard*):ti,ab,kw or 
(pericard*):ti,ab,kw 
22     (aort*):ti,ab,kw or (aneurysm*):ti,ab,kw or (angina*):ti,ab,kw or (arrhythm*):ti,ab,kw or (sick NEXT 
sinus):ti,ab,kw 
23     (ventricular NEXT fibrill*):ti,ab,kw or (atrial NEXT fibrill*):ti,ab,kw or (atherosclero*):ti,ab,kw or 
(arteriosclero*):ti,ab,kw 
24     (#19 OR #20 OR #21 OR #22 OR #23) 
25     (adheren*):ti,ab,kw or (complian*):ti,ab,kw or (concord*):ti,ab,kw 
26     (statin*):ti,ab,kw or (hydroxymethylglutaryl NEXT coa NEXT reductase NEXT inhibitor*):ti,ab,kw or 
(hydroxymethylglutaryl NEXT coenzyme NEXT a NEXT reductase NEXT inhibitor):ti,ab,kw or (hmg NEXT coa 
NEXT reductase NEXT inhibitor*):ti,ab,kw or (ace NEXT inhibitor*):ti,ab,kw 
27     (angiotensin-converting NEXT enzyme NEXT inhibitor*):ti,ab,kw or (calcium NEXT channel NEXT 
block*):ti,ab,kw or (hypotensive*):ti,ab,kw or (cholesterol NEXT absorption NEXT inhibitor*):ti,ab,kw or (bile 
NEXT acid NEXT sequestrant*):ti,ab,kw 
28     (alpha NEXT adrenergic NEAR/1 inhibitor* ):ti,ab,kw or (alpha NEXT adrenergic NEAR/1 block*):ti,ab,kw 
or (alpha NEXT adrenergic NEAR/1 antagonist*):ti,ab,kw 
29     (anti-arrhythm*):ti,ab,kw or (cardiotonic*):ti,ab,kw or (anti-anginal*):ti,ab,kw or (vasodilator*):ti,ab,kw or 
(lower NEAR/3 cholesterol):ti,ab,kw 
30     (lower* NEAR/3 cholesterol):ti,ab,kw or (lower* NEAR/3 blood NEXT pressure):ti,ab,kw or (lower* 
NEAR/3 blood NEXT sugar):ti,ab,kw or (antihypertensive*):ti,ab,kw or (anti-hypertensive*):ti,ab,kw 
31     (oral NEXT hypoglyc*emic*):ti,ab,kw or (antidiabetic*):ti,ab,kw or (anti-diabetic*):ti,ab,kw or 
(anticoagulant*):ti,ab,kw or (anti-coagulant*):ti,ab,kw 
32     (antiplatelet*):ti,ab,kw or (anti-platelet*):ti,ab,kw or (antilipid*emic*):ti,ab,kw or (anti-lipid*emic*):ti,ab,kw 
or (antilip*emic*):ti,ab,kw 
33     (anti-lip*emic*):ti,ab,kw or (hypolip*emic*):ti,ab,kw or (hypolipid*emic*):ti,ab,kw or 
(hypocholesterol*emic*):ti,ab,kw or (anticholesterol*emic*):ti,ab,kw 
34     (anti-cholesterol*emic*):ti,ab,kw or (angiotensin NEXT ii NEXT receptor NEXT antagonist*):ti,ab,kw or 
(arb*):ti,ab,kw or (mineralcorticoid receptor antagonist*):ti,ab,kw or (aldosterone antagonist*):ti,ab,kw 
35     (beta-adrenergic NEAR/2 block*):ti,ab,kw or (beta-adrenergic NEAR/2 inhibitor*):ti,ab,kw or (beta-
adrenergic NEAR/2 antagonist*):ti,ab,kw 
36     (#26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35) 
37     (#25 AND #36) 
38     (#6 OR #11 OR #18 OR #24 OR #37) 
39     (#5 AND #38) 
 
 
OVID Embase (1980-present) 
Searched December 2007; notification alerts monitored until November 2009 
 
1     pharmacist/  
2     pharmacist?.mp.  
3     druggist?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
4     chemist?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
5     pharmacy/  
6     pharmacy.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
7     pharmacies.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
8     pharmaceutical care/  
9     pharmaceutical  
care.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, 
drug manufacturer name]  
10     drugstore?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
64 
 
 
 
manufacturer, drug manufacturer name]  
11     pharmaceutical service?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer name]  
12     1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11  
13     community.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
14     retail.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
15     neighbo?rhood.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer nam 
e]  
16     chain.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
17     13 or 14 or 15 or 16  
18     17 and 12  
19     exp hypertension/  
20     hypertens$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
21     exp blood pressure/  
22     blood pressure.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
23     systolic.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
24     diastolic.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
25     19 or 20 or 21 or 22 or 23 or 24  
26     exp cholesterol/  
27     cholesterol.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
28     high density lipoprotein/  
29     low density lipoprotein/  
30     very low density lipoprotein/  
31     hdl.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
32     ldl.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
33     vldl.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
34     lipoprotein?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
35     dyslipidemia/  
36     dyslipid?em$.mp. [mp=title, abstract, subject he 
adings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]  
37     exp hyperlipidemia/ 
38     hyperlipid?em$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name] 
39     hyperlip?em$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
40     hypercholesterol?em$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer name]  
41     hypertriglycerid?em$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer name]  
42     hyperlipoprotein?em$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer name]  
43     hypolipoprotein?em$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, 
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device manufacturer, drug manufacturer name]  
44     dyslipoprotein?em$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer name]  
45     lip?em$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
46     lipid?em$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name] 
47     dyslip?em$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
48     cholesterol?em$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
49     triglycerid?em$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
50     lipoprotein?em$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer name]  
51     exp triacylglycerol/  
52     triglyceride?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
53     lipid?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
54     exp disorders of lipoprotein metabolism/  
55     26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 
45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54  
56     glucose blood level/  
57     blood glucose.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
58     blood sugar.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
59     hyperglycemia/  
60     hyperglyc?em$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name] 
61     hypergluc?em$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
62     glucose intoleran$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer name]  
63     hypoinsulin?em$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer name]  
64     insulin deficien$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer name]  
65     insulin dependen$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer name]  
66     insulinop?en$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name] 
67     insulin insufficien$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer name]  
68     insulin?em$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
69     glucose intolerance/  
70     hypoinsulinemia/  
71     insulin deficiency/  
72     insulin dependence/ 
73     hemoglobin a1c.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
74     glycosylated hemoglobin a.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer name]  
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75     glycosylated haemoglobin a.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer name]  
76     (a1c adj1 hemoglobin).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer name]  
77     (a1c adj1 haemoglobin).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer name]  
78     hb a1c.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
79     hba1c.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
80     dysglyc?em$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name] 
81     dysgluc?em$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
82     dysinsulin?em$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
83     insulin resistance/  
84     insulin resistan$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
85     metabolic syndrome x/  
86     metabolic syndrome.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer name]  
87     syndrome x.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
88     exp diabetes mellitus/  
89     diabet$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
90     prediabet$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name] 
91     niddm.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
92     56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 
75 or 76 or 77 or 78 or 79 or 80 or 82 or 83 or 84 or 85 or 86 or 87 or 88 or 89 or 90 or 91  
93     exp cerebrovascular disease/  
94     exp cardiovascular disease/  
95     cardio$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
96     vascular.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
97     heart.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
98     cardiac.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
99     coronary.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
100     stroke.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
101     apople$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
102     infarct$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, origin 
al title, device manufacturer, drug manufacturer name]  
103     brain attack?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
104     cerebrovascular.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer name]  
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105     thrombo$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
106     embol$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
107     isch?em$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
108     myocard$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
109     pericard$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
110     aort$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
111     aneurysm$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
112     angina$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
113     arrhythm$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
114     sick sinus.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
115     ventricular fibrill$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer name]  
116     atrial fibrill$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
117     atherosclero$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
118     arteriosclero$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
119     93 or 94 or 95 or 96 or 97 or 98 or 99 or 100 or 101 or 102 or 103 or 104 or 105 or 106 or 107 or 108 or 109 
or 110 or 111 or 112 or 113 or 114 or 115 or 116 or 117 or 118  
120     patient compliance/  
121     adheren$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
122     complian$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
123     concord$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
124     120 or 121 or 122 or 123  
125     exp cardiovascular agent/  
126     exp antidiabetic agent/  
127     statin?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
128     hydroxymethylglutaryl coa reductase inhibitor?.mp. [mp=title, abstract, subject headings, heading word, drug 
trade name, original title, device manufacturer, drug manufacturer name]  
129     hydroxymethylglutaryl coenzyme a reductase inhibitor?.mp. [mp=title, abstract, subject headings, heading 
word, drug trade name, original title, device manufacturer, drug manufacturer name]  
130     hmg coa reductase inhibitor?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer name]  
131     exp dipeptidyl carboxypeptidase inhibitor/  
132     ace inhibitor?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
133     angiotensin-converting enzyme inhibitor?.mp. [mp=title, abstract, subject headings, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer name]  
134     exp calcium channel blocking agent/  
135     calcium channel block$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original 
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title, device manufacturer, drug manufacturer name]  
136     hypotensive?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
137     cholesterol absorption inhibitor?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer name]  
138     bile acid sequestrant?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer name]  
139     exp adrenergic receptor blocking agent/  
140     ((alpha-adrenergic or beta-adrenergic) adj1 (inhibitor? or block$ or antagonist?)).mp. [mp=title, abstract, 
subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]  
141     anti-arrhythm$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
142     cardiotonic?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
143     anti-anginal?.mp. [mp=title, abstract, subject headings, heading word,  
drug trade name, original title, device manufacturer, drug manufacturer name]  
144     vasodilator$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
145     antihypertensive?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer name]  
146     anti-hypertensive?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer name]  
147     oral hypoglyc?emic?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer name]  
148     antidiabetic?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
149     anti-diabetic?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, 
 original title, device manufacturer, drug manufacturer name]  
150     anticoagulant?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
151     anti-coagulant?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer name]  
152     antiplatelet?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
153     anti-platelet?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
154     antilipid?emic?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer name]  
155     anti-lipid?emic?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer name]  
156     antilip?emic?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
157     anti-lip?emic?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
158     hypolip?emic?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer name]  
159     hypolipid?emic?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer name]  
160     hypocholesterol?emic?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer name]  
161     anticholesterol?emic?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer name]  
162     anti-cholesterol?emic?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer name]  
163     exp aldosterone antagonist/  
69 
 
 
 
164     aldosterone antagonist?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer name]  
165     angiotensin 2 receptor antagonist/  
166     angiotensin ii receptor antagonist?.mp. [mp=title, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer name]  
167     angiotensin ii receptor block$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer name]  
168     arb?.mp.  
169     (lower$ adj3 cholesterol).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer name]  
170     (lower adj3 blood sugar).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer name]  
171     (lower$ adj3 blood pressure).mp. [mp=title, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer name]  
172     125 or 126 or 127 or 128 or 129 or 130 or 131 or 132 or 133 or 134 or 135 or 136 or 137 or 138 or 139 or 140 
or 141 or 142 or 143 or 144 or 145 or 146 or 147 or 148 or 149 or 150 or 151 or 152 or 153 or 154 or 155 or 156 or 
157 or 158 or 159 or 160 or 161 or 162 or 163 or 164 or 165 or 166 or 167 or 168 or 169 or 170 or 171  
173     124 and 172  
174     25 or 55 or 92 or 119 or 173  
175     18 and 174  
 
 
OVID International Pharmaceutical Abstracts (1970-present) 
Searched December 2007; notification alerts monitored until November 2009 
 
1     pharmacist?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
2     druggist?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
3     chemist?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
4     pharmacy.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
5     pharmacies.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
6     drugstore?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
7     pharmaceutical care.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
8     pharmaceutical service?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
9     1 or 2 or 3 or 4 or 5 or 6 or 7 or 8  
10     community.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
11     retail.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
12     chain.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
13     neighbo?rhood.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
14     10 or 11 or 12 or 13  
15     14 and 9  
16     hypertens$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
17     blood pressure.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
18     systolic.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
19     diastolic.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
20     16 or 17 or 18 or 19  
21     cholesterol.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
22     hdl.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
23     ldl.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
24     vldl.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
25     lipoprotein?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
26     dyslipid?em$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
27     hyperlipid?em$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
28     hyperlip?em$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
29     hypercholesterol?em$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
30     hypertriglycerid?em$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
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31     hyperlipoprotein?em$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
32     hypolipoprotein?em$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
33     dyslipoprotein?em$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
34     lip?em$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
35     lipid?em$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
36     dyslip?em$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
37     cholesterol?em$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
38     triglycerid?em$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
39     lipoprotein?em$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
40     triglyceride?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
41     lipid?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
42     21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 
40 or 41  
43     blood glucose.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
44     blood sugar.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
45     hyperglyc?em$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
46     hypergluc?em$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
47     glucose intoleran$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
48     hypoinsulin?em$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
49     insulin deficien$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
50     insulin dependen$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
51     insulinop?en$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
52     insulin insufficien$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
53     insulin?em$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
54     glycosylated hemoglobin a.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic 
name]  
55     glycosylated haemoglobin a.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic 
name]  
56     (a1c adj1 hemoglobin).mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
57     (a1c adj1 haemoglobin).mp. [mp=title, subject heading word, registry word, abstract, trade name/generic 
name]  
58     hb a1c.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
59     hba1c.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
60     dysglyc?em$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
61     dysgluc?em$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
62     dysinsulin?em$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
63     insulin resistan$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
64     metabolic syndrome.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
65     syndrome x.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
66     diabet$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
67     prediabet$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
68     niddm.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
69     43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 63 or 
64 or 65 or 66 or 67 or 68  
70     cardio$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
71     vascular.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
72     heart.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
73     cardiac.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
74     coronary.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
75     stroke.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
76     apople$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
77     infarct$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
78     brain attack?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
79     cerebrovascular.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
80     thrombo$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
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81     embol$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
82     isch?em$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
83     myocard$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
84     pericard$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
85     aort$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
86     aneurysm$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
87     angina$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
88     arrhythm$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
89     sick sinus.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
90     ventricular fibrill$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
91     atrial fibrill$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
92     atherosclero$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
93     arteriosclero$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
94     70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 or 85 or 86 or 87 or 88 or 
89 or 90 or 91 or 92 or 93  
95     adheren$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
96     complian$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
97     concord$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
98     95 or 96 or 97  
99     statin?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
100     hydroxymethylglutaryl coa reductase inhibitor?.mp. [mp=title, subject heading word, registry word, abstract, 
trade name/generic name]  
101     hydroxymethylglutaryl coenzyme a reductase inhibitor?.mp. [mp=title, subject heading word, registry word, 
abstract, trade name/generic name]  
102     hmg coa reductase inhibitor?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic 
name]  
103     ace inhibitor?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
104     angiotensin-converting enzyme inhibitor?.mp. [mp=title, subject heading word, registry word, abstract, trade 
name/generic name]  
105     calcium channel block$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic 
name]  
106     hypotensive?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
107     cholesterol absorption inhibitor?.mp. [mp=title, subject heading word, registry word, abstract, trade 
name/generic name]  
108     bile acid sequestrant?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
109     (alpha adrenergic adj1 (inhibitor? or block$ or antagonist?)).mp. [mp=title, subject heading word, registry 
word, abstract, trade name/generic name]  
110     anti-arrhythm$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
111     cardiotonic?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
112     anti-anginal?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
113     vasodilator$.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
114     (lower adj3 cholesterol).mp. [mp=title, subject heading word, registry word, abstract, trade name/generic 
name]  
115     (lower? adj3 cholesterol).mp. [mp=title, subject heading word, registry word,  
abstract, trade name/generic name]  
116     (lower? adj3 blood pressure).mp. [mp=title, subject heading word, registry word, abstract, trade name/generic 
name]  
117     (lower? adj3 blood sugar).mp. [mp=title, subject heading word, registry word, abstract, trade name/generic 
name]  
118     antihypertensive?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
119     anti-hypertensive?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
120     oral hypoglyc?emic?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
121     antidiabetic?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
122     anti-diabetic?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
123     anticoagulant?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
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124    anti-coagulant?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
125     antiplatelet?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
126     anti-platelet?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
127     antilipid?emic?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
128     anti-lipid?emic?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
129     antilip?emic?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
130     anti-lip?emic?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
131     hypolip?emic?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
132     hypolipid?emic?.mp. [mp=title, subject heading word, registry word, abstract, trade name/g 
eneric name]  
133     hypocholesterol?emic?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic 
name]  
134     anticholesterol?emic?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
135     anti-cholesterol?emic?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic 
name]  
136     angiotensin ii receptor antagonist?.mp. [mp=title, subject heading word, registry word, abstract, trade 
name/generic name]  
137     arb?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic name]  
138     mineralcorticoid receptor antagonist?.mp. [mp=title, subject heading word, registry word, abstract, trade 
name/generic name]  
139     aldosterone antagonist?.mp. [mp=title, subject heading word, registry word, abstract, trade name/generic 
name]  
140     (beta-adrenergic adj2 (block$ or inhibitor? or antagonist?)).mp. [mp=title, subject heading word, registry 
word, abstract, trade name/generic name]  
141     99 or 100 or 101 or 102 or 103 or 104 or 105 or 106 or 107 or 108 or 109 or 110 or 111 or 112 or 113 or 114 
or 115 or 116 or 117 or 118 or 119 or 120 or 121 or 122 or 123 or 124 or 125 or 126 or 127 or 128 or 129 or 130 or 
131 or 132 or 133 or 134 or 136 or 137 or 139 or 140  
142     98 and 141  
143     20 or 42 or 69 or 94 or 142  
144     15 and 143  
 
 
OVID MEDLINE (1950-present)  
Searched December 2007; notification alerts monitored until November 2009 
 
1     pharmacists/  
2     pharmacist?.mp.  
3     druggist?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
4     chemist?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
5     pharmacies/  
6     pharmacy.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
7     pharmacies.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
8     drugstore?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
9     pharmaceutical care.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
10     pharmaceutical service?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
11     1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10  
12     community.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
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13     retail.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]  
14     chain.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]  
15     neighbo?rhood.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
16     12 or 13 or 14 or 15  
17     16 and 11  
18     community pharmacy services/  
19     17 or 18  
20     exp hypertension/ 
21     hypertens$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
22     exp blood pressure/  
23     blood pressure.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
24     systolic.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
25     diastolic.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
26     20 or 21 or 22 or 23 or 24 or 25  
27     exp cholesterol/  
28     cholesterol.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
29     exp lipoproteins hdl/  
30     exp lipoproteins ldl/  
31     exp lipoproteins vldl/  
32     hdl.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]  
33     ldl.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]  
34     vldl.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]  
35     exp dyslipidemias/  
36     lipoprotein?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
37     dyslipid?em$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
38     hyperlipid?em$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
39     hyperlip?em$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
40     hypercholesterol?em$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
41     hypertriglycerid?em$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
42     hyperlipoprotein?em$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
43     hypolipoprotein?em$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
44     dyslipoprotein?em$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
45     lip?em$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
46     lipid?em$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
47     dyslip?em$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
48     cholesterol?em$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
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49     triglycerid?em$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
50     lipoprotein?em$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
51     exp triglycerides/  
52     triglyceride?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
53     lipid?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]  
54     27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 
46 or 47 or 48 or 49 or 50 or 51 or 52 or 53  
55     blood glucose/  
56     blood glucose.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
57     blood sugar.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
58     exp hyperglycemia/  
59     hyperglyc?em$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
60     hypergluc?em$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
61     glucose intoleran$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
62     hypoinsulin?em$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
63     insulin deficien$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
64     insulin dependen$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
65     insulinop?en$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
66     insulin insufficien$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
67     insulin?em$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
68     hemoglobin a glycosylated/  
69     glycosylated hemoglobin a.mp. [mp=title, original title, abstract, name of substance word, subject heading 
word, unique identifier]  
70     glycosylated haemoglobin a.mp. [mp=title, original title, abstract, name of substance word, subject heading 
word, unique identifier]  
71     (a1c adj1 hemoglobin).mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
72     (a1c adj1 haemoglobin).mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
73     hb a1c.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]  
74     hba1c.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]  
75     dysglyc?em$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
76     dysgluc?em$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
77     dysinsulin?em$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
78     insulin resistan$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
79     metabolic syndrome.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
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80     syndrome x.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
81     exp diabetes mellitus/  
82     diabet$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]  
83     diabet$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]  
84     prediabet$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
85     niddm.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]  
86     exp hyperinsulinism/  
87     55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 
74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 or 85 or 86  
88     exp cerebrovascular disorders/  
89     exp cardiovascular diseases/  
90     cardio$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]  
91     vascular.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
92     heart.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]  
93     cardiac.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]  
94     coronary.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
95     stroke.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]  
96     apople$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
97     infarct$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
98     brain attack?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
99     cerebrovascular.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
100     thrombo$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
101     embol$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
102     isch?em$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
103     myocard$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
104     pericard$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
105     aort$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]  
106     aneurysm$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
107     angina$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
108     arrhythm$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
109     sick sinus.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
110     ventricular fibrill$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
111     atrial fibrill$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
112     atherosclero$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
113     arteriosclero$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
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identifier]  
114     88 or 89 or 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or  
98 or 99 or 100 or 101 or 102 or 103 or 104 or 105 or 106 or 107 or 108 or 109 or 110 or 111 or 112 or 113  
115     patient compliance/  
116     adheren$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
117     complian$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
118     concord$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
119     115 or 116 or 117 or 118  
120     exp antilipemic agents/  
121     exp cardiovascular agents/ 
122     exp hypoglycemic agents/  
123     statin?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
124     hydroxymethylglutaryl coa reductase inhibitor?.mp. [mp=title, original title, abstract, name of substance 
word, subject heading word, unique identifier]  
125     hydroxymethylglutaryl coenzyme a reductase inhibitor?.mp. [mp=title, original title, abstract, name of 
substance word, subject heading word, unique identifier]  
126     hmg coa reductase inhibitor?.mp. [mp=title, original title, abstract, name of substance word, subject heading 
word, unique identifier]  
127     exp angiotensin-converting enzyme inhibitors/  
128     ace inhibitor?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
129     angiotensin-converting enzyme inhibitor?.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word, unique identifier]  
130     exp calcium channel blockers/ 
131     calcium channel block$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
132     hypotensive?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
133     cholesterol absorption inhibitor?.mp. [mp=title, original title, abstract, name of substance word, subject 
heading word, unique identifier]  
134     bile acid sequestrant?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
135     exp adrenergic alpha-antagonists/  
136     (alpha adrenergic adj1 (inhibitor? or block$ or antagonist?)).mp. [mp=title, original title, abstract, name of 
substance word, subject heading word, unique identifier]  
137     anti-arrhythm$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
138     cardiotonic?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
139     anti-anginal?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
140     vasodilator$.mp. [mp=title, original title, abstract, name of substance w 
ord, subject heading word, unique identifier]  
141     (lower$ adj3 cholesterol).mp. [mp=title, original title, abstract, name of substance word, subject heading 
word, unique identifier]  
142     antihypertensive?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
143     anti-hypertensive?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
144     oral hypoglyc?emic?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
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145     antidiabetic?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
146     anti-diabetic?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
147     anticoagulant?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
148     anti-coagulant?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
149     antiplatelet?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
150     anti-platelet?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
151     antilipid?emic?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
152     anti-lipid?emic?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
153     antilip?emic?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
154     anti-lip?emic?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
155     hypolip?emic?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
156     hypolipid?emic?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
157     hypocholesterol?emic?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
158     anticholesterol?emic?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
159     anti-cholesterol?emic?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
160     angiotensin ii receptor antagonist?.mp. [mp=title, original title, abstract, name of substance word, subject 
heading word, unique identifier]  
161     exp angiotensin ii type 1 receptor blockers/  
162     arb?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]  
163     mineralcorticoid receptor antagonist?.mp. [mp=title, original title, abstract, name of substance word, subject 
heading word, unique identifier]  
164     exp aldosterone antagonists/  
165     aldosterone antagonist?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
166     exp adrenergic beta-antagonists/  
167     (beta-adrenergic adj2 (block$ or inhibitor? or antagonist?)).mp. [mp=title, original title, abstract, name of 
substance word, subject heading word, unique identifier]  
168     (lower$ adj3 blood pressure).mp. [mp=title, original title, abstract, name of substance word, subject heading 
word, unique identifier]  
169     (lower$ adj3 blood sugar).mp. [mp=title, original title, abstract, name of substance word, subject heading 
word, unique identifier]  
170     120 or 121 or 122 or 123 or 124 or 125 or 126 or 127 or 128 or 129 or 130 or 131 or 132 or 133 or 134 or 135 
or 136 or 137 or 138 or 139 or 140 or 141 or 142 or 1 
43 or 144 or 145 or 146 or 147 or 148 or 149 or 150 or 151 or 152 or 153 or 154 or 155 or 156 or 157 or 158 or 159 
or 160 or 161 or 162 or 163 or 164 or 165 or 166 or 167 or 168 or 169  
171     119 and 170  
172     26 or 54 or 87 or 114 or 171  
173     19 and 172  
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CINAHL search strategy (1982-present) 
Searched June 2007 
 
1     Pharmacists/  
2     pharmacist?.mp.  
3     druggist?.mp.  
4     chemist?.mp.  
5     Pharmacy, Retail/  
6     pharmacy.mp.  
7     pharmacies.mp.  
8     drugstore?.mp.  
9     pharmaceutical care.mp.  
10     pharmaceutical service.mp.  
11     1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10  
12     community.mp.  
13     (retail or chain or neighbo?rhood).mp.  
14     12 or 13  
15     exp Hypertension/  
16     hypertens$.mp.  
17     exp Blood Pressure/  
18     systolic.mp.  
19     diastolic.mp.  
20     blood pressure.mp.  
21     15 or 16 or 17 or 18 or 19 or 20  
22     Cholesterol/  
23     cholesterol.mp.  
24     exp Lipoproteins, HDL/  
25     exp Lipoproteins, LDL/  
26     hdl.mp.  
27     ldl.mp. [mp=title, original title, abstract, name of substance, word, subject heading word, unique identifier]  
28     vldl.mp. [mp=title, original title, abstract, name of substance, word, subject heading word, unique identifier]  
29     exp Hyperlipidemia/  
30     lipoprotein?.mp.  
31     dyslipid?em$.mp.  
32     hyperlipid?em$.mp.  
33     hyperlip?em$.mp.  
34     hypercholesterol?em$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
35     hypertriglycerid?em$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
36     hyperlipoprotein?em$.mp.  
37     hypolipoprotein?em$.mp.  
38     dyslipoprotein?em$.mp.  
39     lip?em$.mp.  
40     lipid?em$ mp.  
41     dyslip?em$.mp.  
42     cholesterol?em$.mp.  
43     triglycerid?em$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
44     lipoproteinem$.mp.  
45     triglycerides/  
46     triglyceride?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
47     lipid?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]  
48     22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 
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41 or 42 or 43 or 44 or 45 or 46 or 47  
49     blood glucose/  
50     blood glucose.mp.  
51     blood sugar.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
52     hyperglycemia/  
53     hyperglyc?em$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
54     hypergluc?em$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
55     glucose intoleran$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
56     hypoinsulin?em$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
57     insulin deficien$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
58     insulin dependen$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
59     insulinop?en$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
60     insulin insufficien$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
61     insulin?em$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
62     hemoglobin a, glycosylated/  
63     glycosylated hemoglobin a.mp. [mp=title, original title, abstract, name of substance word, subject heading 
word, unique identifier]  
64     glycosylated haemoglobin a.mp. [mp=title, original title, abstract, name of substance word, subject heading 
word, unique identifier]  
65     (a1c adj1 hemoglobin).mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
66     (a1c adj1 haemoglobin).mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
67     hb a1c.mp. [mp=title, original title, abstract, name of substance, word subject heading word, unique identifier]  
68    hba1c.mp. [mp=title, original title, abstract, name of substance, word subject heading word, unique identifier]  
69     dysglyc?em$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
70     dysgluc?em$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
71     dysinsulin?em$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
72     insulin resistan$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
73     metabolic syndrome.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
74     syndrome x.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
75     exp diabetes mellitus/  
76     glucose intolerance/  
77     exp insulin resistance/  
78     diabet$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]  
79     prediabet$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
80     niddm.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]  
81     49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 
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68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80  
82     exp cerebrovascular disorders/  
83     exp cardiovascular diseases/  
84     cardio$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]  
85     heart.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]  
86     cardiac.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]  
87     coronary.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
88     stroke.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]  
89     apople$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
90     infarct$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
91     brain attack?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
92     cerebrovascular.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
93     thrombo$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
94     embol$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]  
95     isch?em$.mp. [mp=title, original title, abstract, name of substance word, subject  
heading word, unique identifier]  
96     myocard$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
97     pericard$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
98     aort$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]  
99     aneurysm$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
100     angina$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
101     arrythm$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
102     sick sinus.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
103     ventricular fibrill$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
104     atrial fibrill$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
105     atherosclero$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
106     arteriosclero$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
107     82 or 83 or 84 or 85 or 86 or 87 or 88 or 89 or 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99 or 100 
or 101 or 102 or 103 or 104 or 105 or 106  
108     exp patient compliance/  
109     adheren$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
110     complian$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
111     concord$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
112     108 or 109 or 110 or 111  
113     exp antilipemic agents/  
114     exp cardiovascular agents/  
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115     exp hypoglycemic agents/  
116     exp statins/  
117     statin?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
118     hydroxymethylglutaryl coa reductase inhibitor?.mp. [mp=title, original title, abstract, name of substance 
word, subject heading word, unique identifier]  
119     hydroxymethylglutaryl coenzyme a reductase inhibitor?.mp. [mp=title, original title, abstract, name of 
substance word, subject heading word, unique identifier]  
120     hmg coa reductase inhibitor?.mp. [mp=title, original title, abstract, name of substance word, subject heading 
word, unique identifier]  
121      angiotensin converting enzyme inhibitor?.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word, unique identifier]  
122     ace inhibitor?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
123     calcium channel block$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
124     hypotensive?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
125     cholesterol absorption inhibitor?.mp. [mp=title, original title, abstract, name of substance word, subject 
heading word, unique identifier]  
126     bile acid sequestrant?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
127     exp adrenergic antagonists/  
128     (alpha or beta) adj1 adrenergic adj1 (inhibitor? or block$ or antagonist?)).mp. [mp=title, original title, 
abstract, name of substance word, subject heading word, unique identifier]  
129     anti-arrhythm$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
130     cardiotonic?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
131     anti-anginal?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
132     vasodilator$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
133     (lower$ adj3 cholesterol).mp. [mp=title, original title, abstract, name of substance word, subject heading 
word, unique identifier]  
134     (lower$ adj3 blood pressure).mp. [mp=title, original title, abstract, name of substance word, subject heading 
word, unique identifier]  
135     antihypertensive?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier] 
136     anti-hypertensive?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
137     oral hypoglyc?emic?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
138     antidiabetic?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
139     anti-diabetic?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
140     anticoagulant?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
141     anti-coagulant?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
142     antiplatelet?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
143     anti-platelet?.mp. [mp> =title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
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144     antilipid?emic?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
145     anti-lipid?emic?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
146     antilip?emic?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
147     anti-lip?emic?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier] ( 
148     hypolip?emic?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
149     hypolipid?emic?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier]  
150     hypocholesterol?emic?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
151     anticholesterol?emic?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
152     anti-cholesterol?emic?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
153     angiotensin ii receptor antagonist?.mp. [mp=title, original title, abstract, name of substance word, subject 
heading word, unique identifier]  
154     angiotensin ii receptor blocker?.mp. [mp=title, original title, abstract, name of substance word, subject 
heading word, unique identifier]  
155     arb?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]  
156     mineralcorticoid receptor antagonist?.mp. [mp=title, original title, abstract, name of substance word, subject 
heading word, unique identifier]  
157     aldosterone antagonist?.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier]  
158     113 or 114 or 115 or 116 or 117 or 118 or 119 or 120 or 121 or 122 or 123 or 124 or 125 or 126 or 127 or 128 
or 129 or 130 or 131 or 132 or 133 or 134 or 135 or 136 or 137 or 138 or 139 or 140 or 141 or 142 or 143 or 144 or 
145 or 146 or 147 or 148 or 149 or 150 or 151 or 152 or 153 or 154 or 155 or 156 or 157  
159     112 and 158  
160     21 or 48 or 81 or 107 or 159  
161     11 and 14  
162     160 and 161  
 
 
OAISTER (www.oaister.org) 
Searched August 2009 
Pharmacist* in title and cardiovascular in entire record 
 
 
ProQuest Dissertations and Theses (1951-present) 
Searched December 2007 
(Pharmacist* or druggist* or chemist* or pharmacy or pharmacies or drugstore* or pharmaceutical care) and 
(community or retail or chain or neighborhood or neighbourhood) in title 
 
 
Theses Canada Portal (http://collectionscanada.ca/thesescanada) 
Searched August 2009 
Title/keyword search for pharmacist or pharmacists  
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- Chapter 4 -  
 
A PRAGMATIC CLUSTER RANDOMIZED TRIAL EVALUATING THE IMPACT OF 
A COMMUNITY PHARMACY INTERVENTION ON STATIN ADHERENCE: 
RATIONALE AND DESIGN OF THE COMMUNITY PHARMACY ASSISTING IN 
TOTAL CARDIOVASCULAR HEALTH (CPATCH) STUDY 
 
4.1 Abstract 
 
Background:  Traditional randomized controlled trials are considered the gold standard for 
evaluating the efficacy of a treatment.  However, in adherence research, limitations to this study 
design exist, especially when evaluating real-world applicability of an intervention.  Although 
adherence interventions by community pharmacists have been tested, problems with internal and 
external validity have limited the usefulness of these studies, and further well-designed and well-
conducted research is needed.  We aimed to determine the real-world effectiveness of a 
community pharmacy adherence intervention using a robust study design. This novel design 
integrates cluster randomization and an outcome evaluation of medication adherence using a 
population-based administrative data source in the province of Saskatchewan, Canada.     
 
Methods:   Community pharmacies from across the province of Saskatchewan, Canada were 
randomized to deliver an adherence intervention to their patients or usual care.  Intervention 
pharmacies were trained to employ a practical adherence strategy targeted at new users of statin 
medications.  While randomization and implementation of the intervention occurred at the 
community pharmacy level, the outcome analysis will occur at the level of the individual 
patients.  The primary outcome is the mean statin adherence among all eligible new users of 
statin medications.  Secondary outcomes include the proportion of new statin users who exhibit 
adherence ≥80%, and persistence with statin use.   
 
Conclusion:  This novels study design was developed to combine the rigor of a randomized trial 
with a pragmatic approach to implementing and capturing the results in a real-world fashion.  We 
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believe this approach can serve as an example for future study designs evaluating practice-based 
adherence interventions.    
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4.2 Introduction 
Randomized controlled trials (RCT) are considered the gold standard design for the evaluation of 
treatment efficacy,1 and are increasingly being used for evaluating interventions aimed at 
improving medication adherence.2  However, in adherence research, limitations to this study 
design exist.  First, traditional RCTs require that all study participants are informed and 
consenting volunteers.  This requirement likely pre-selects individuals who are at a lower risk for 
non-adherence, particularly for RCTs of behavioural interventions.  Indeed, patients enrolling in 
clinical trials may be systematically different from those declining to participate.2,3  In addition, 
when traditional RCT designs are used, the same health care professional is often forced to 
provide the adherence intervention and ‘usual care’ concurrently.4,5  Clearly, contamination is 
unavoidable when the same health practitioner is providing the control and experimental 
conditions simultaneously.3   
 
Because of their accessibility and frequent interactions with patients, community pharmacists are 
considered ideally situated to deliver interventions aimed at improving medication adherence.3  
However, adherence interventions by community pharmacists have not consistently shown 
benefits.3,6  One of the reasons may be that these studies are often plagued with methodological 
problems.  Many studies do not report a power calculation, do not utilize proper randomization 
techniques or allocation concealment, and most do not provide adequate details of the 
intervention when reporting the results.7  Furthermore, generalizability of successful 
interventions is often low because most health care professionals do not have the time or 
resources to implement complex study protocols.8-11  As a result, little is known about the extent 
to which community pharmacists can influence adherence in real world settings.    
 
We describe the design of a study aimed at evaluating the real-world effectiveness of an 
adherence intervention provided by community pharmacies; the Community Pharmacy Assisting 
in Total Cardiovascular Health (CPATCH) study.  This prospective study employs a novel 
design that integrates cluster randomization with an evaluation of all at-risk patients using an 
administrative database.  The design presented herein was developed to strengthen the external 
validity of research studies that examine adherence interventions while maintaining the high 
standards required for prospective clinical trials.  Although the general CPATCH strategy is 
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intended to be employable with all cardiovascular medications, this study is focused on the 
prevention of non-adherence among new users of statin medications.  Statin medications were 
chosen for this initial study, as it is well known that 40% to 50% of all new statin users become 
non-adherent within the first year,12,13 and a sizeable proportion discontinue the medication after 
only one dispensation.14 
 
4.3 Methods 
Recruitment of Community Pharmacies 
In the Fall 2009, all community pharmacies across the province of Saskatchewan (n=357) were 
invited to enrol in the CPATCH study.  Advertisements were placed in bulletins and newsletters 
distributed by provincial pharmacy organizations.  Also, individual letters were mailed to all 
pharmacy owners/managers in the province and the study investigators advertised in person at 
various local pharmacy conferences and events.   
 
Community pharmacies interested in enrolling were directed to the study coordinating centre at 
the University of Saskatchewan to determine their eligibility.  Pharmacies were eligible for 
enrollment if: i) they filled at least 85 total statin prescriptions during a consecutive 6 week 
period; ii) the owner/manager indicated that this adherence intervention would be given priority 
over all other study initiatives offered by the pharmacy staff; and iii) all members of the 
pharmacy (dispensary) staff provided informed consent.  
 
Randomization 
The CPATCH study employed a clustered randomized trial design whereby community (retail) 
pharmacies were randomized into one of two groups: an intervention group that received training 
to provide the CPATCH adherence strategy to their patients; and a usual care group that did not 
receive any specialized adherence training and will provide their patients with standard care.   
A computer generated randomization list, in permuted blocks of 6, was created by an employee 
at the Drug Information centre at the University of Saskatchewan who is not an investigator in 
this study.  Each randomly allocated group assignment (intervention or usual care) was 
individually sealed in sequential, opaque envelopes and kept in the office of the Drug 
Information Centre.  Given the nature of the intervention, it was impossible for the study 
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investigators and pharmacy researchers (i.e. participating pharmacies) to be blinded to the group 
assignments; however, all study researchers were blinded to the sequence generation, and all 
allocations were concealed until the study group was assigned. Furthermore, randomization was 
carried out in multiples of 6 (i.e., six pharmacies were randomized at a time) to ensure that the 
investigators had no opportunity to anticipate which group a pharmacy would be allocated to.   
 
The Intervention   
Pharmacies (i.e. pharmacists and pharmacy technicians) randomized to the intervention group 
received training on how to implement the CPATCH support program within their store; the 
control pharmacies did not receive any training, and were intentionally not given any indication 
of the focus of the study intervention (adherence of new statin users).  Training on the CPATCH 
strategy was provided through a 2.5 hour workshop delivered in a setting outside the dispensary.  
Briefly, the training program introduced a simple and coordinated strategy to consistently 
identify and support patients at high risk for statin non-adherence.  The criteria used to identify 
individuals at high-risk for non-adherence were based on epidemiologic observations of statin 
use.  Specifically, individuals receiving their first dispensation for a statin medication have a 
40%-50% risk of becoming non-adherent in the first year of therapy.12,13  Further, many patients 
will discontinue after only one dispensation.14  These dispensation patterns were used to provide 
objective evidence regarding the risk for non-adherence associated with new prescriptions of 
these medications.  Also, these data were used to justify our hypothesis that initial statin 
dispensation encounters are critical to the prevention of non-adherence.   
 
The CPATCH strategy was designed specifically to be implemented into real-world community 
pharmacy practice without the need for additional resources or significant changes to existing 
workflow procedures.  As a result, the program is flexible to each specific pharmacy.  The 
consistent elements of the overall CPATCH training strategy are: i) routine identification of new 
users (those in their first year of therapy) of statin medications as they present for each 
dispensation; ii) consistent assessment for barriers to non-adherence at every dispensation for at-
risk patients (new users); iii) a paradigm shift from traditional counselling to an approach that 
focuses on patient preparation and reassurance; preparation for the negative messages about 
statins they will likely hear in the coming months and reassurance that this medication is backed 
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by objective evidence, and iv) a commitment by pharmacy staff to actively respond to identified 
adherence barriers such as cost, intolerance, lack of knowledge, or beliefs about the medication.  
The focus of this strategy is to lower the incidence of non-adherence rather than remedy those 
patients with already established non-adherence.  
 
Subjects 
Intervention pharmacies will identify patients within the first year of statin therapy through 
dispensation records and face-to-face encounters.  Although intervention pharmacies will target 
all statin users within their first year of therapy, data will only be collected on those patients 
who: i) receive a new statin prescription from a study pharmacy (intervention or control) during 
the observation period; ii) have no statin fills recorded during the year prior to the index 
prescription (first fill for a statin medication during the study observation period); and iii) have 
been continuously enrolled as a Saskatchewan Drug Plan beneficiary for at least 365 days prior 
to the index prescription.  These study patients will be identified independently by personnel 
from the Saskatchewan Ministry of Health and all outcome data will be collected at the 
administrative database level (see “Follow-up”).            
 
The observation period for each pharmacy will begin two weeks after their training session.  This 
two week lag period will be used to allow each staff to implement the strategy and resolve any 
issues with the help of the CPATCH investigators.  To ensure consistency between groups, usual 
care pharmacies were assigned a start date that matched the date of an intervention pharmacy 
falling most closely in the order of randomization.  As a result, in each permuted block of six 
randomized pharmacies, three pairs (one control and one intervention) of stores will share the 
same start date.   
 
Follow-up 
All patient information and outcome data will be collected from administrative databases 
maintained by the Saskatchewan Ministry of Health (Sask Heath). Sask Health maintains a 
registry and several databases containing health services records such as prescription drug data, 
hospital services data, and physician services data (Table 4.1).  Health services information 
captured by distinct databases can be linked at the patient level through a unique identification 
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number for each individual.  These databases have served as the basis for many observational 
studies because they capture data on the vast majority of Saskatchewan residents.15-18  For this 
study, the databases will be used to capture health services utilization (prescriptions, physician 
visits and hospitalizations) including diagnoses on all eligible subjects.  
  
All Saskatchewan residents are eligible for provincial health insurance coverage, except inmates 
of federal penitentiaries and members of the Royal Canadian Mounted Police and Canadian 
Forces (less than 1% of the Saskatchewan population). All health insurance beneficiaries are 
eligible for Saskatchewan Drug Plan benefits except those who receive these benefits from 
another government agency, primarily registered Indians (about 9% of the population). Therefore 
about 10% of the Saskatchewan population is ineligible for the study because of no or 
incomplete capture of health services information. 
 
The researchers will provide Sask Health with the list of participating pharmacies and their 
specific Saskatchewan Drug Plan identifiers (i.e., provider identifier), and enrolment dates. Sask 
Health personnel will extract all statin prescriptions dispensed from the participating pharmacies 
during the 18 months following the pharmacy’s enrolment date. The individuals receiving these 
prescriptions will form the pool of potential new statin-users. The prescription histories of the 
potential pool members will be reviewed to determine which subjects are new statin-users. 
Hospital, physician and prescription information for eligible new statin-users will be compiled 
and de-identified prior to release to the researchers for analysis. 
 
It is estimated that each pharmacy will need six months to accrue their sample size of new statin 
users, thereby allowing 12 months for follow up.  However, because it will not be possible to 
determine when each pharmacy’s sample size has been met, data will be collected on all new-
users presenting to each pharmacy throughout the observation period.  Patients will be followed 
from one year prior to their index prescription until the end of the pharmacy’s observation 
period, death, or loss of beneficiary status, whichever is sooner.  
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Outcomes 
Although community pharmacies are the unit of randomization, our primary outcome is the mean 
adherence among all eligible new users of statin medications who have been followed up for at 
least 12 months past their index prescription.  This primary outcome will be measured at the 
individual level.  All statin dispensations for each subject will be captured by the prescription 
drug plan database and mean adherence will be measured using the proportion of days covered 
(PDC),19,20 adjusted for any days that a subject may be hospitalized during the observation 
period.  The PDC is calculated by taking the sum of the days’ supply for all statin prescription 
fills during the study period, divided by the number of days of observation. Study participants 
who have statin dispensations from non-study pharmacies will be captured and accounted for 
using methods previously published.21  Secondary outcomes include the proportion of new statin 
users who exhibit adherence (PDC) ≥80%, and the persistence with statin use among patients 
with a minimum of 12 months of follow up.  Persistence is defined as the number of days from 
the index prescription to the earliest occurrence of study end date or date of discontinuation 
(assumed when a refill is not obtained within 102 days of finishing the estimated supply).22,23  
Only those subjects with a minimum of 6 months of follow-up will be included in the secondary 
analyses.   
 
Sample Size 
Using data from a previous observational study evaluating one-year statin adherence of new 
users at 34 different community pharmacies in Saskatchewan,21 we were able to estimate an 
intracluster (or intraclass) correlation coefficient (ICC) of 0.0143, and determine that mean statin 
adherence in this population was 0.71 (SD 0.13). Thus, in order to detect a 15% improvement in 
mean adherence, considered to be clinically important,24,25 with 80% power at a p < 0.05, 270 
subjects would be required in each group. The community pharmacies enrolled in CPATCH are 
expected to accrue a minimum of 25 subjects over a 6 month period.  As a result, 22 clusters 
(pharmacies) are needed, but 30 will actually be enrolled as the planned statistical analysis 
requires a minimum of 15 clusters within each group.26   
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Statistical Methods   
Baseline characteristics will be compared between groups using both cluster and individual-level 
variables (Table 4.2).  To determine the effect of the intervention, mean adherence will be 
measured at one year using generalized estimating equations (GEE) with an exchangeable 
correlation matrix and robust standard errors, with individuals as the analytical unit.27  Both 
univariate and multivariable models will be developed based on individual and pharmacy-level 
variables considered statistically significant (P<0.10), or clinically important (e.g. age, sex) 
(Tables 4.2).  To estimate the extent to which the intervention was implemented in each 
pharmacy, pharmacy team staff members will record the names of all new users identified during 
the course of their day-to-day practice.  At the end of each month, a pharmacy staff member will 
compare the number of identified patients recorded on the list to the total number of new users 
who received a statin prescription based on their electronic dispensation records.  These 
“screening rates” will be reported to the investigators monthly, and will be adjusted for in the 
final models.  All first order interactions will be tested. 
 
Two secondary endpoints, the proportion of new statin users who exhibit optimal adherence 
(≥80%) at one-year, and mean persistence will be measured on an individual level and analyzed 
using GEE with an exchangeable correlation matrix and robust standard errors.  All analyses will 
be intention-to-treat, and will include any pharmacies that have withdrawn, as well as any 
individual subjects who are no longer beneficiaries of the Saskatchewan Drug Plan (due to death 
or coverage termination).  Mean imputation will be used for subjects or pharmacies lost-to-
follow-up. 
 
Ethics approval for the study protocol was obtained from the University of Saskatchewan 
Biomedical Ethics Board (09-135).  The study is registered at ClinicalTrials.gov no. 
NCT00971412. 
 
4.4 Discussion 
Medication non-adherence is a global problem28 that consumes substantial financial health care 
resources,29 and has been recognized as a predictor of negative patient outcomes.17,30  Non-
adherence is complicated and multifactorial,31 and health interventions that are aimed at 
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improving it are often not evaluated using pragmatic study designs.  Recognizing this, we have 
utilized a novel study design evaluating an intervention involving community pharmacies, aimed 
at improving medication adherence.   
 
A CRT design was selected for this study for two reasons.  First, the intervention is intended for 
implementation at the community pharmacy level, so it is logical that community pharmacies 
would be the unit of randomization.  Second, this design will lessen the risk for experimental 
contamination because pharmacists will not be forced to provide intervention and usual care 
activities at the same time.32  We can not rule out the potential for the Hawthorne effect33 within 
the usual care pharmacies; however, the effect is likely minimal as this group was intentionally 
not given any indication of the focus of the study intervention (adherence of new statin users).  
Also, this design will eliminate the need to recruit, obtain consent, and randomize individual 
patients, which is often impractical in typical community pharmacy settings. 
 
We were prudent in following the guidelines for cluster randomized trials outlined in the 
CONSORT statement,34 ensuring that the risk of contamination between groups will be 
minimized, while maintaining the integrity of the experimental group comparison.  Because the 
intervention will be evaluated in all new statin users presenting to each pharmacy, it will enhance 
the external validity of this study.  Also, by ensuring all patient data are collected at arms length 
(by the Saskatchewan Ministry of Health), pharmacists can implement the adherence support 
strategy on all patients without the administrative burden of obtaining patient consent and 
collecting study specific information.   
 
In addition, we have also provided the ICC used in estimating our sample size.  To our 
knowledge, this ICC is the first one to be published in this particular field of research.  We hope 
this value will prove useful in the design of future studies as well as encourage other researchers, 
especially in the area of medication adherence, to share their ICCs or cluster specific event rates.   
 
4.5 Conclusion  
We have presented, in detail, the design of the CPATCH study.  Our approach combines the 
rigor of a randomized trial with a pragmatic approach to implementing and recording the results 
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in a real-world fashion.  We believe this approach can serve as an example of study design for 
the evaluation of future practice-based adherence interventions in large randomized trials.    
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Table 4.1. Relevant Data Elements Available from Saskatchewan Health Databases18 
 
 
 
Database 
 
 
Available Data 
 
Prescription drug 
 
 
 
 
 
Hospital services 
 
 
 
 
 
 
Physician services 
 
 
 
 
 
Insurance registry 
 
Patient information 
Drug information 
Prescriber information 
Dispensing pharmacy information 
Cost information 
 
 
Patient information 
Diagnostic and procedure information (based 
on ICD-10-CAa and CCIb) 
Admission and discharge dates 
Length of hospital stay 
 
 
Patient information 
Physician information 
Diagnostic information (3 digit ICD-9c code) 
Billing information 
 
 
Beneficiary information (effective date, end 
date, sex, age, residence) 
 
 
a. International Statistical Classification of Disease and Related Health Problems, Tenth Revision, Canada35 
b. Canadian Classification of Health Interventions36 
c. International Classification of Disease, Ninth Revision  
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Table 4.2.  Individual and Pharmacy Level Variables Available for Multivariable Analysis  
 
Variable Description Database Source 
 
Individual Level  
 
Sex 
 
 
Age 
 
 
Income security benefits 
 
 
 
Concurrent medications 
 
 
 
 
 
 
 
 
Prior cardiovascular event 
 
 
 
 
 
 
 
 
 
 
 
Study cardiovascular event 
 
 
 
 
 
 
 
 
 
 
 
 
Chronic disease score 
 
 
 
Prior hospitalizations 
 
 
 
Study hospitalizations 
 
 
Physician visits  
 
 
 
 
 
Sex of patient 
 
 
Age of patient at index date (calculated using date of birth) 
 
 
Patient receives income security benefit (a proxy for 
socioeconomic status) 
 
 
Concurrent medications use during one year prior to patient’s 
index date, and for the first 6 months of the study observation 
period.  
     Beta blockers 
     Angiotensin converting enzyme inhibitors 
     ASA 
     Oral hypoglycemics 
 
 
Cardiovascular event(s) in one year prior to patient’s index date 
(Based in ICD-10-CA classifications) 
     Myocardial infarction (I21. – I23.) 
     Stroke (all causes) (I60. – I64.) 
     Transient ischemic attack (G45.0) 
     Unstable angina (I20.0) 
     Other ischemic heart disease (I24. – I25.) 
     Revascularization procedures 
         PTCA (1.IJ.50, 1.IJ.57.GQ, 1.IL.35), CABG (1.IJ.76) 
     Coronary Angiography (3.IP.10)      
 
 
Cardiovascular event(s) in during study observation period 
 (Based in ICD-10-CA classifications) 
     Myocardial infarction (I21. – I23.) 
     Stroke (all causes) (I60. – I64.) 
     Transient ischemic attack (G45.0) 
     Unstable angina (I20.0) 
     Other ischemic heart disease (I24. – I25.) 
     Revascularization procedures 
         PTCA (1.IJ.50, 1.IJ.57.GQ, 1.IL.35), CABG (1.IJ.76) 
     Coronary Angiography (3.IP.10)          
 
 
 
Chronic disease score (measure of chronic disease status derived 
from population-based automated pharmacy data)37 
 
 
Number of hospitalizations in one year prior to patient’s index 
date 
 
 
Number of hospitalizations during study observation period 
 
 
Number of physician visits during and prior to observation 
 
 
 
 
 
Insurance registry 
 
 
Insurance registry 
 
 
Prescription drug 
 
 
 
Prescription drug 
 
 
 
 
 
 
 
 
Hospital services 
 
 
 
 
 
 
 
 
 
 
 
Hospital services 
 
 
 
 
 
 
 
 
 
 
 
 
Prescription drug 
 
 
 
Hospital services 
 
 
 
Hospital services  
 
 
Physician services 
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Variable Description Database Source 
 
 
Pharmacy Level  
 
Pharmacy type 
 
 
 
Pharmacy location 
 
 
 
 
Prescription volume 
 
 
 
Pharmacist coverage 
 
 
Technician support  
 
Monthly screening rates 
 
 
 
Indicates the type of pharmacy (mass merchandise, chain/grocery, 
independent)38 
 
 
Rural (population<10,000) 
Regional (population 10,000 – 100,000) 
Urban (population >100,000) 
 
 
Mean number of new statin prescriptions filled monthly (proxy 
measure for prescription volume) 
 
 
Pharmacist overlap or single pharmacist   
 
 
Pharmacy technician support  
 
Proportion of new users identified by pharmacy staff (proxy 
measure of the extent that the identification component of the 
intervention was performed) 
 
 
 
 
Investigators to 
categorize 
 
 
Investigators to 
categorize 
 
 
 
Prescription drug 
 
 
 
Pharmacy survey 
 
 
Pharmacy survey 
 
Pharmacy staff 
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- Chapter 5 -  
 
PATTERNS OF ADHERENCE IN THE FIRST YEAR OF ANTIHYPERTENSIVE 
THERAPY: AN OBSERVATIONAL STUDY 
 
 
5.1 Abstract 
 
Background:  Adherence to chronic medications is poor.  The first year of therapy has been 
associated with the highest probability for non-adherence, and studies of statin medications have 
suggested that a significant proportion of first year non-adherence is due to discontinuation after 
only a single dispensation (first-fill discontinuations).  Studies examining utilization of 
antihypertensive (AHT) medications rarely report patterns of adherence specific to the first year 
of therapy.  Also, the majority of studies report that adherence is significantly better with 
angiotensin-receptor blockers (ARBs) compared to other categories of AHT agents.  The purpose 
of this study was to address two specific questions: 1) what proportion of non-adherence in the 
first year of AHT therapy is due to first-fill discontinuations? and 2) are ARBs associated with 
improved adherence compared to other AHT agents? 
 
Methods:  This retrospective cohort study utilized data from linked administrative databases in 
the province of Saskatchewan. Eligible subjects were 40 years of age or older and had received a 
new AHT prescription between 1994 and 2002.  The primary endpoint for the first study 
question was the proportion of non-adherent subjects who discontinued their AHT after the first 
dispensation (i.e. first-fill discontinuation).  For the second research question, the cohort was 
restricted to a subgroup of individuals receiving monotherapy.  The primary endpoint for the 
second research question was the proportion of subjects achieving optimal adherence at one year 
stratified by AHT category.  Further analyses specifically compared adherence between ARBs, 
angiotensin converting enzyme inhibitors (ACEIs) and non-dihydropyridine calcium channel 
blockers (Non-DHP), and between ARBs and ARB + hydrochlorothiazide combinations.  
Adherence was estimated using the cumulative mean gap ratio measure. 
 
102 
 
 
 
Results:  A total of 52,125 subjects were eligible.  The proportion of subjects with optimal 
adherence (≥80%) at one year was 50.4% (26,285/52,125).  First fill discontinuations occurred in 
38.9% (10,054/25,840) of non-adherent subjects.  In subjects receiving monotherapy only, 
adherence varied between the different AHT categories.  Optimal adherence (≥80%) was 
observed in 59.9%, 67.2%, and 53.0% of subjects initiating ARBs (losartan) [245/409], ACEI 
(ramipril) [1097/1632], and non-DHP (amlodipine) [473/893] respectively.  Compared to 
losartan, the adjusted odds for achieving optimal adherence was not significantly different for 
users of ramipril (adjusted OR 1.28, 95% CI 0.99 – 1.643, p=0.05) or amlodipine (adjusted OR 
0.81, 95% CI 0.63 – 1.05, p=0.12).  Adherence was high in both the ARB (1013/1600 [63.3%]) 
and ARB + HCTZ (305/453 [67.3%]) categories, and no significant difference was found 
between them (adjusted OR 1.16, 95% CI 0.92 – 1.46, p=0.20).    
 
Conclusion: A substantial proportion of non-adherence to AHT medications can be attributed to 
subjects who discontinue after only a single fill of medication.  Adherence to AHT medications 
is poor across all categories and it is unlikely that specific agents, such as ARBs, are 
independently associated with optimal adherence.   
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5.2 Introduction   
It is well known that adherence to chronic medications is poor,1 and the first year of therapy has 
been consistently associated with the highest probability for non-adherence.2-5  Studies of 
adherence to statin medications have indicated that non-adherence in the first year of therapy can 
be frequently attributed to individuals who discontinue after only a single dispensation (“first-fill 
discontinuations”).3, 6  However, it is not clear whether these observations reflect a statin-specific 
non-adherence pattern or a pattern of non-adherence related to cardiovascular, or chronic disease, 
medications in general.  Typically, studies of antihypertensive (AHT) medications have reported 
discontinuation rates after one year of therapy, with results ranging from 28%7 to 43%.8  Few 
studies have specifically examined whether first-fill discontinuations contribute to non-
adherence in the first year in other widely prescribed cardiovascular medications, like AHT 
therapy.   
 
Available studies suggest AHT medications are associated with varying levels of non-adherence 
depending on the category prescribed.  Specifically, several investigators have reported that 
subjects taking angiotensin-receptor blockers (ARBs) are significantly more likely to 
demonstrate good adherence and/or persistence compared to those taking other AHT agents.7-15  
Previously, authors have speculated that improved adherence is likely due to the more favourable 
side effect profile of ARBs.7, 12  As the determinants of adherence are complex and 
multifactorial,1, 2 we hypothesized that the association between ARB use and good adherence is 
likely due to confounding or bias overlooked in the previous studies rather than any specific 
characteristics of a single AHT medication category.    
 
The purpose of this study was to address two specific questions: 1) what proportion of non-
adherence in the first year of AHT therapy is due to first-fill discontinuations? and 2) is ARB use 
independently associated with improved adherence compared to other AHT medications?     
 
5.3 Methods  
We created a cohort of subjects who were new users of AHT therapy between January 1, 1994 
and December 31, 2002 using the linked administrative databases from the province of 
Saskatchewan, Canada. The Saskatchewan Ministry of Health maintains several health services 
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databases including prescription drug data, physician services utilization, hospital services 
utilization, and vital statistics.  Health services information captured by these distinct databases 
can be linked electronically at the individual level through a unique identification number.  All 
Saskatchewan residents are eligible for provincial health insurance coverage, except inmates of 
federal penitentiaries and members of the Royal Canadian Mounted Police and Canadian Forces 
(less than 1% of the Saskatchewan population); approximately 90% of the Saskatchewan 
population is eligible for prescription drug coverage.  Residents ineligible for coverage under the 
drug plan are primarily Registered Indians who have their prescription costs paid for by another 
government agency.16  These databases have served as the basis for many observational studies 
of medication adherence and are considered to be of high quality.4, 17-19   
 
To be eligible, subjects must have been at least 40 years of age and filled a new AHT 
prescription in one of the following pre-specified categories: beta blockers, angiotensin 
converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), non-dihydropyridine 
calcium channel blocker (Non-DHP CCB), dihydropyridine calcium channel blocker (DHP 
CCB), thiazide diuretic, potassium-sparing diuretic; or one of the following combination 
products: ACEI + hydrochlorothiazide (HCTZ), ARB + HCTZ, beta blocker + diuretic, and 
potassium-sparing diuretic + HCTZ (Appendix C).  A new prescription was defined as having no 
dispensations for any AHT agent in the 5 years prior to the first AHT prescription (index date).   
 
In an attempt to ensure that the AHT was being prescribed for uncomplicated hypertension (i.e., 
without significant comorbidities), we excluded all subjects who had a history of hospitalization 
or outpatient physician services in the previous 5 years for any of the following: cardiovascular 
events (e.g. myocardial infarction, unstable angina, congestive heart failure), diabetes, 
HIV/AIDS, renal or liver disease, esophageal varices, or solid organ transplant.   The observation 
period began on the first AHT prescription dispensation (i.e., index date) and continued for 1 
year (365 days).  Because medication use during hospital stays is not captured by the 
Saskatchewan Drug Plan, subjects who were hospitalized for any reason during the observation 
period were excluded.  To ensure reliable estimates of adherence for all patients, only subjects 
with a full 365 days of follow-up (i.e. still receiving Saskatchewan Health and prescription 
benefits) were included in the analysis.   
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First Fill Discontinuations: 
The primary endpoint for the first study question was the proportion of non-adherent subjects 
who discontinued their AHT after the first dispensation (i.e. first-fill discontinuation).  Because 
many individuals receiving AHT therapy require concurrent combinations from multiple AHT 
categories, accurately determining non-adherence can be complex.  For example, it is not clear 
how to classify patients that are selectively adherent to one AHT medication but not another.20, 21  
Therefore, we defined non-adherence as the failure to obtain enough AHT medication to cover ≥ 
80% of the observation period (365 days) with at least one AHT medication, regardless of the 
total number of different AHT categories prescribed during that period.20  For example, a subject 
who initially filled an ACE inhibitor and then subsequently switched to a beta-blocker would be 
considered adherent if sufficient medication was available between the agents to cover 80% of 
the observational period. The 80% threshold is easily defined and is commonly used in studies 
measuring adherence.5, 17, 22   
 
Adherence was estimated with the cumulative mean gap ratio (the number of days when 
medication was unavailable in relation to the total number of days of the observation period).23  
This was calculated by dividing the number of days that any AHT medication was unavailable 
(due to a delayed refill or discontinuation) by the number of days in the observation period, then 
subtracting that number from 1 to obtain an adherence value.23, 24  In Saskatchewan, AHT 
prescriptions are primarily dispensed on a monthly (34 day) basis, so we calculated the number 
of days medication was unavailable by subtracting the expected gap (34 days) from the actual 
gap (number of days between AHT dispensation dates).  Although Saskatchewan pharmacies 
may dispense diuretic prescriptions in larger quantities (100-day supplies), the majority of all 
diuretic dispensations (89.6%) were dispensed in quantities not exceeding 34 tablets. Negative 
values indicated early refills, and therefore a surplus of medication; positive values indicated late 
refills, and a period of days when medication was not available.  To account for oversupply, we 
subtracted the total number of days of surplus medications from the total days of unavailable 
medication (assuming that all dispensed medications would be consumed in their entirety).  For 
individuals taking only a single medication, this cumulative gap calculation is mathematically 
identical to the “fill frequency” measure that has been previously used with Saskatchewan data.4, 
17, 25   
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Adherence Associated with ARBs versus Other AHT Categories 
For the second research question, we restricted the overall cohort of all AHT users to a subgroup 
of individuals receiving monotherapy only.  These subjects were identified by excluding all those 
who filled medications from >1 AHT category during the one-year follow-up period (i.e., if they 
switched to a different category of AHT, or had an AHT medication added); however, switching 
medications within the same category was allowed.  The primary endpoint was the proportion of 
subjects achieving optimal adherence at one year stratified by AHT category (Appendix C).   
 
In a secondary analysis, we repeated the adherence analysis by restricting the cohort to those 
who were prescribed either losartan (ARB), ramipril (ACEI), or amlodipine (DHP CCB) as their 
initial therapy.  Losartan was chosen as a comparator because it was the first ARB released into 
the Canadian market (1995), and was the most frequently (25.6%) prescribed ARB in our cohort.  
Ramipril and amlodipine were selected as comparators because they shared the closest Canadian 
release date to losartan (ramipril 1997, amlodipine 1992), and they were only available as brand 
name formulations throughout the entire study period.  Therefore, these cohorts were composed 
of subjects receiving “newly” marketed AHT medications where no generic substitute was 
available.  The final analysis compared adherence rates between subjects receiving any ARB 
medication and those receiving ARB + HCTZ combination products to evaluate the influence of 
a diuretic on the adherence of these medications (Appendix C).   
 
Sensitivity Analyses  
We performed a number of sensitivity analyses to evaluate the robustness of our results.  First, to 
ensure inclusion of medication oversupply was not influencing our study results, we excluded 
medication oversupply from our adherence calculation by setting all surplus medication values to 
0, and then summed all days where medication was unavailable (i.e., assuming all previously 
dispensed medications were discarded or not taken).  Second, we re-calculated adherence after 
modifying the “days supply” variable to 30 and 40 days in place of 34.  Third, because the 
Saskatchewan Drug Plan did not collect a “days supply” variable during the study period, we 
conducted a sensitivity analysis using 2 alternate adherence measures.  First, we calculated the 
“tablets per day” by dividing the total number of tablets dispensed during the observation period 
by the number of days in the observation period (365 days).3  Second, we employed a modified 
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proportion of days covered (PDC) in which we used the individual drug monographs of the most 
commonly prescribed AHT in each category (Appendix 1) to estimate a days supply variable by 
dividing the quantity of tablets/capsules in each dispensation by the recommended daily 
regimen.25  The estimated days supply variable was then divided by the number of days in the 
observation period.  Finally, we compared adherence of other ARBs (candesartan, irbesartan, 
telmisartan, and valsartan) to ramipril and amlodipine. 
 
Statistical Analysis  
Baseline characteristics were compared using ANOVA and chi-square, where appropriate.  
Crude proportions for optimal adherence between the individual AHT categories were compared 
using chi-square. Multivariate logistic regression was used to adjust for confounding factors that 
may have influenced the proportion of subjects exhibiting optimal adherence or discontinuing 
after the first fill.  The following covariates were either statistically significant (p<0.1) or 
considered to be clinically relevant for both models: sex, age at index, Von Korff chronic disease 
score26 (a well validated measure of comorbidity derived from medication usage) at index, 
income security benefits at index (a proxy measure for socioeconomic status), year that the index 
prescription was dispensed, and number of physician visits during the observation year, as 
adherence may be higher in subjects receiving regular follow-up.27  We also adjusted for 
concurrent dispensations of the following medications during the observation year: oral diabetes 
medications and/or insulin, nitrates, statins, ASA, warfarin, and antidepressants.  Additionally, 
we estimated the overall prescription burden by totalling the number of selected non-AHT 
prescription medication classes filled (Appendix C) during the observation year.  All first order 
interactions were tested, with none being clinically significant (p>0.1).  All analyses were carried 
out using SPSS version 16.0 for Windows (SPSS Inc, Chicago, IL), and Stata SE, version 10 
(Stata, College Station, Texas).  Because all data were de-identified by Saskatchewan Ministry of 
Health personnel prior to being sent to the investigators, the study protocol was granted a letter 
of exemption by the University of Saskatchewan Biomedical Research Ethics Board.  
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5.4 Results  
First Fill Discontinuations 
We identified 67,939 subjects who were newly initiated on AHT therapy between January 1994 
and December 2002 with 52,125 (the overall cohort) having a minimum follow-up of 365 days 
without being hospitalized (Figure 5.1).   The mean age of this cohort was 59.4 (SD 12.6) years, 
mean chronic disease score was 2.9 (SD 1.8),26 and 42% were male (Table 5.1).  Of the overall 
cohort, 15,911 (30.5%) subjects filled more than one category of AHT during the first year of 
therapy (Figure 5.1).  The proportion of subjects with optimal adherence (≥80%) at one year was 
50.4% (26,285/52,125) when accounting for oversupply with any type of AHT medication.  Of 
the 25,840 subjects who were non-adherent at one year, 10,054 (38.9%) discontinued after the 
first dispensation (first fill discontinuation).  First fill discontinuations were associated with 
younger age, female gender, and use of an antidepressant medication during the observation 
period.  In contrast, subjects who filled their index prescription from 1996 onwards, and those 
who visited their physician more often were less likely to discontinue their AHT after the first 
fill.  Also, concurrent use of ASA, statins, and diabetes therapy in the observation year were 
associated with fewer discontinuations after the first AHT fill (Table 5.2). 
 
Adherence Associated with ARBs versus Other AHT Categories 
A total of 36,214 subjects filled one AHT category exclusively throughout the first year; these 
individuals were termed the “monotherapy” cohort (Figure 5.1).  The mean age at the index date 
was 59 years (SD 12.7), and 40% of subjects were male (Table 5.3).  Subjects were relatively 
healthy, with a mean chronic disease score of 2.9 (SD 1.8).26  Compared to the overall cohort, the 
monotherapy cohort had slightly fewer males; mean age and CDS at index were similar.  
Statistically significant differences between AHT monotherapy categories were observed for all 
baseline characteristics; however, few clinically important differences could be identified, except 
for a lower proportion of men in the thiazide and potassium-sparing + HCTZ groups (Table 5.3).   
 
Optimal adherence was observed in 39.8% (14,405/36,214) of the monotherapy subjects, and 
significant differences were observed between the 10 medication categories (Figure 5.2).  The 
highest rates of optimal adherence (≥80%) were associated with use of ARB + HCTZ (64.2%), 
ACEI + HCTZ (61.9%), ARB (61.1%) and ACEI (58.3%).  Female subjects, those who were 
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older, and had a lower chronic disease score at index were more likely to have optimal 
adherence, as were those with concurrent use of statin and ASA therapy during the observation 
year.  Subjects who visited their physician more frequently and those with an index date after 
1996 were also more likely to exhibit optimal adherence (Table 5.4). 
 
When comparing the ARB category (represented by losartan) specifically to the ACEI 
(represented by ramipril) and DHP CCB (represented by amlodipine) categories, optimal 
adherence (≥80%) was observed in 59.9% (245/409), 67.2% (1097/1632), and 53.0% 473/893), 
respectively, which clearly contrasted the pooled rate of 39.8%.  Compared to losartan, the 
adjusted odds for achieving optimal adherence was not significantly different for users of 
ramipril (adjusted OR 1.28, 95% CI 0.99 – 1.64, p=0.05) or amlodipine (adjusted OR 0.81, 95% 
CI 0.63 – 1.05, p=0.12).  Similarly, no significant difference was found between the proportion 
of subjects achieving optimal adherence on the combination of an ARB + HCTZ (305/453 
[67.3%]) compared to those on an ARB (1013/1600 [63.3%]; adjusted OR 1.16, 95% CI 0.92 – 
1.46, p=0.20).   
 
Interestingly, a pattern seemed to emerge when AHT categories were arranged chronologically 
by their release year into the Canadian market.  Subjects in the most recently released AHT 
categories appear to exhibit better adherence compared to those receiving AHT medications 
released earlier (Figure 5.3).  To further examine this trend, we compared only drugs within the 
ACEI class and found an almost identical pattern; those drugs released most recently had better 
adherence than did those drugs released earlier (data not shown).  
 
Sensitivity results 
First, analyses that excluded medication oversupply from our adherence calculation (i.e., setting 
all surplus medication values to 0) yielded comparable results to our main findings, except that 
only 38.2% (19,886/52,125) of subjects in the overall cohort were classified as adherent (≥80%) 
at one year.  Furthermore, the proportion of non-adherent subjects discontinuing after the first fill 
was also comparable at 31.2% (10,054 / 32,239).  Second, when adherence was calculated using 
an expected gap of 30 days and 40 days adherence rates were similar at 45.4% (26,663/52,125) 
and 54.5% (28,529/52,125) to the overall cohort findings.  Both alternative methods of 
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calculating adherence provided similar results for the monotherapy cohort using either the tablets 
per day method (13,967/36,214 [38.6%]) or the modified PDC (16,036/36,214 [44.3%]).  
Finally, when compared to ramipril and amlodipine, candesartan, irbesartan, telmisartan, and 
valsartan all showed similar results to when losartan was used (data not shown). 
 
5.5 Discussion  
In this retrospective cohort study nearly half (49.6%) of subjects who were newly initiated on 
AHT medications were classified as non-adherent (<80%) after one year.  Of these non-adherent 
subjects, 40% failed to obtain any further AHT medication after the first dispensation.  When 
comparing the various AHT categories, the proportion of monotherapy subjects with optimal 
adherence ranged from 64.2% (ARB + HCTZ) to 22.9% (potassium-sparing diuretic + HCTZ).  
However, our findings strongly suggest that the association between adherence and specific AHT 
agents may be influenced by factors that are unrelated to pharmacologic differences.     
 
To the best of our knowledge, this is the first paper to specifically examine the prevalence of 
first-fill discontinuations on non-adherence to AHT medications.  Two previous publications 
have briefly commented on discontinuations after only a single fill, and reported almost identical 
rates of 18%28 and 19%.29  However, neither study was specifically evaluating this outcome and 
presented rates that were not specific to non-adherent subjects;28, 29 also, we could not be certain 
that their study population consisted only of new users.29   
 
Our findings are worrisome as non-adherence to AHT therapy has been identified as a major 
cause of inadequate blood pressure control, leaving patients at significant risk for complications 
related to hypertension.30  Given the significant impact that first-fill discontinuations have on 
non-adherence to AHT therapy, we believe that interventions aimed at improving adherence 
should be focused on those subjects presenting with a first ever prescription.  Also, we find it 
extremely interesting that this pattern of non-adherence is virtually identical to that of statins, 
which exhibit completely different biologic and adverse effects than AHT medications.   
 
Similar to previous studies, the initial comparison of adherence rates between the individual 
AHT classes appear to suggest that adherence is best with ARBs and poorest with diuretics.11, 13, 
111 
 
 
 
14  However, we further compared adherence between only those subjects receiving a 
representative drug from each of the ARB (losartan), ACEI (ramipril) and DHP CCB 
(amlodipine) groups.  By doing so, we attempted to minimize selection bias as all 3 drugs were 
marketed at relatively the same time, and were only available as brand name formulations 
throughout the entire study period.  After covariate adjustment, neither the ACEI (ramipril) nor 
DHP CCB (amlodipine) groups differed significantly from the ARB (losartan) group.  Indeed, it 
appeared that adherence was better in the AHT categories that were most recently released on the 
Canadian market.  Interestingly, we found an almost identical pattern when comparing drugs 
within the ACEI category only; subjects receiving ACEIs that were released most recently had a 
better adherence than did those who received drugs released earlier.   
   
In an attempt to test the idea that the tolerability and adverse effect profiles of different AHT 
classes (especially diuretics) may be responsible for non-adherence,31, 32 we compared adherence 
and for subjects in the ARB and ARB + HCTZ categories.  Despite containing a diuretic, which 
has been associated with poor adherence11, 14, 15, 28 presumably caused by troublesome side 
effects,32 adherence was not appreciably different between the categories.   
 
Our findings suggest that external factors may be more strongly linked to adherence than the 
pharmacologic properties of certain AHT medications.  For example, newer medications may be 
perceived as “better”, and therefore they may be prescribed for patients who demonstrate a 
strong motivation to control/treat their hypertension; or, they may be prescribed 
disproportionately to patients who seem to be able to afford them.  Regardless of the cause, it 
does appear that those patients receiving ARBs are different from those typically receiving drugs 
from other AHT categories.  Bourgault et al found that subjects initiated on ARBs were more 
likely to initiate a new course of AHT therapy (any category) if they discontinued their initial 
ARB compared to those initiated on other AHT agents.10  Certainly, more research in this area is 
warranted, especially now that ARBs are no longer the newest AHT category available. 
 
There are several limitations which must be considered when examining the results.  First, we 
only evaluated subjects after one year of therapy, and therefore can not comment on adherence 
past the first year.  However, as the first year of therapy has been identified as the highest risk 
112 
 
 
 
period for non-adherence,2-5 we believe these results are still important.  Second, we restricted 
part of our analyses to subjects who only received one AHT category in the first year.  Because 
of this we cannot be sure if these patterns are influenced by concurrent AHT therapy.  Despite 
this, our study sample was large and we had representation from all different categories of 
AHTs.  Also, we did include all new users of AHT therapy to evaluate the proportion of subjects 
who discontinued after the first fill.  Third, it is possible that not all subjects were prescribed an 
AHT for hypertension.  Specifically, certain subjects may have been receiving treatment for 
conditions that were more acute and periodic, such as transient edema, or migraine prophylaxis.  
However, we did employ a hypertension definition comparable to similar observational studies 
using administrative data,7, 33 and attempted to ensure that the AHT agent had been prescribed 
solely for uncomplicated hypertension by excluding all subjects who were previously 
hospitalized for any complicating reason in the previous 5 years.  Fourth, as with all 
administrative database studies, we assumed that filling a prescription meant the medication was 
actually taken. Although this assumption would appear to be realistic,24 we cannot say with 
complete certainty that the medication was consumed.  Also, administrative databases inherently 
lack detailed patient-level clinical information so we were unable to assess the reasons for non-
adherence. Further, we can not be certain that systematic differences in blood pressure or other 
clinical characteristics were equally distributed amongst our cohorts.  However, baseline 
comparisons appear to indicate that subjects were indeed similar.  Fifth, because days supply was 
not captured by Saskatchewan Health and Extended Benefits Branch during the period of this 
study, we had to estimate it.  However, the majority of the drugs in the analysis were dispensed 
on a monthly (34 days) basis, and we performed two sensitivity analyses which demonstrated 
similar results.  Finally, although the first ARB (losartan) was released into the Canadian market 
on December 31, 1995, it did not receive an unrestricted listing on the Saskatchewan Formulary 
until July 1, 1997.13  Because of this, we are unable to say with complete certainty that all 
subjects in the ARB category were new users.  However, only a small proportion (5.3%) of the 
1600 subjects in the ARB category had an index date before July 1, 1998, and therefore could 
not be verified as a new user by at least one previous year of no AHT use. 
 
 
 
113 
 
 
 
5.6 Conclusion   
The results from the present study confirm that a substantial proportion of non-adherence to 
AHT medications can be attributed to patients who discontinue after only a single dispensation.  
Also, adherence to AHT medications is poor across all categories and it is unlikely that specific 
categories, such as ARBs, are independently associated with optimal adherence.  Given that non-
adherence to AHT medications is not only associated with an increase in blood pressure, but also 
an increase in vascular events, hospitalizations, and healthcare costs,33, 34 adherence strategies 
aimed at patients presenting with their first ever AHT prescription for any AHT category will 
likely have a significant impact.   
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Figure 5.1. Selection of Study Subjects 
 
 
Reasons for Exclusion: 
-Index prescription filled on January 1, 2003 (n=11)  
-More than one AHT categories in observation 
period: 
   -2 (n=11,418) 
   -3 (n=3,402) 
   -4 (n=845) 
   -5 (n=186) 
   -6 (n=38) 
   -7 (n=10) 
   -8 (n=1) 
Overall cohort: 
Minimum 365 days follow-up after first 
antihypertensive prescription  
 
n= 52,125 
Monotherapy cohort: 
Only received one AHT category in the 
first year  
 
Reasons for Exclusion: 
-Hospitalization in observation year (n=7,874) 
-Death (n=312) 
-Coverage terminated (n=372) 
-First prescription filled <365 days prior to study end 
(December 31, 2003) (n=7,267) 
n= 36,214 
All new users of antihypertensive 
agents (1994 – 2003) 
 
n= 67,939 
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Figure 5.2. Proportion of Monotherapy Cohort with Adherencea ≥80% (n=36,214) 
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a.    Cumulative gap measure   
ARB       Angiontensin receptor blocker 
BB         Beta blocker 
ACEI      Angiotensin converting enzyme inhibitor 
CCB      Calcium channel blocker 
DHP     Dihyrdopyridine 
HCTZ   Hydrochlorothiazide  
K           Potassium  
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Figure 5.3. Proportion of Monotherapy Cohort with Adherencea ≥80%:Drug Categories 
 Arranged Chronologicallyb [left to right] According to Release Date into Canadian Market 
 
 
0
10
20
30
40
50
60
70
80
Ov
era
ll
Th
iaz
ide
s
K-
sp
ari
ng
 + 
HC
TZ BB
CC
B (
No
nD
HP
)
CC
B (
DH
P)
AC
EI
AC
EI 
+ H
CT
Z
BB
 + 
Th
iaz
ide AR
B
AR
B +
 H
CT
Z
%
Adjusted
Unadjusted 
 
a.  Cumulative gap measure  
b.  Although captopril (ACEI) was released prior to CCB (Non DPH), it only accounted for 0.1% of our study cohort.  Therefore, we placed the ACEI chronologically 
based on when the utilized ACEI were marketed in Canada. 
K Potassium  
HCTZ Hydrochlorothiazide  
BB Beta blockers 
CCB  Calcium channel blockers 
DHP Dihydropyridine 
ARB Angiotensin receptor blockers 
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Table 5.1. Baseline Characteristics of Overall Cohort (n=52,125) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristic  
 
n 
Subjects 
 
52,125 
Mean age (years) at index (SD) 
 
59.4 (12.5) 
Male (%) 
 
21623 (41.5) 
 
Mean CDS at index (SD) 
 
2.9 (1.8) 
 
Index year (%) 
   1994 
   1995 
   1996 
   1997 
   1998 
   1999 
   2000 
   2001 
   2002 
 
4249 (8.2) 
4666 (9.0) 
4615 (8.9) 
5539 (10.6) 
5600 (10.7) 
6296 (12.1) 
6905 (13.2) 
7147 (13.7) 
7063 (13.6) 
 
Physician visitsa in  
observation year (%) 
   0 
   1-3 
   4-11 
   12+ 
 
 
 
391 (0.8) 
4907 (9.4) 
28017 (53.7) 
18810 (36.1) 
 
Total concurrent non-AHT medications in 
observation year (%) 
   0 
   1-2 
   3-4 
   5+ 
 
 
21355 (41.0) 
25072 (48.1) 
5029 (9.6) 
669 (1.3) 
Concurrent non-AHT medication in observation 
year (%) 
   Diabetes / Insulin 
   Nitrates 
   Statins 
   ASA 
   Warfarin 
   Antidepressants  
 
 
802 (1.5) 
2035 (3.9) 
4301 (8.3) 
1059 (2.0) 
571 (1.1) 
6951(13.3) 
 
Income security benefitsb (%) 
   None 
   SAP 
   Family-based 
   Senior-based 
 
 
41242 (79.1) 
1371 (2.6) 
557 (1.1) 
8955 (17.2) 
a. Number of distinct days  where at least 1 service was provided to an individual subject by as Saskatchewan physician  
b. None, no income security benefits; SAP, a program of last resort for families and individuals who, for various reasons, including disability, illness, low income or 
unemployment, cannot meet basic living costs;  Family-based, supplements the financial resources of low-income families with dependent children – eligibility based on 
annual family income and assets; Senior-based, supplementary income for subjects ≥65 years who have little or no income other than the federal Old Age Security 
pension and Guaranteed Income Supplement 
SD      Standard deviation 
CDS   Chronic disease score (Von Korff)26 
AHT   Antihypertensive  
SAP   Saskatchewan Assistance Program  
 
 
 
 
Table 5.2. Predictors of Discontinuation After First Fill for Overall Cohort Subjects with Adherencea <80% 
 
Predictor     n  Unadjusted OR  Adjusted OR  P Value 
       (95% CI)   (95% CI) 
 
Sex 
Male     10462     -      -       
Female     15378  1.318 (0.1252 – 1.387) 1.319 (1.250 – 1.391) <0.0001   
 
Age     25840  0.9897 (0.985 – 0.989) 0.990 (0.998 – 0.992) <0.0001 
 
Income Security Benefitb 
None     20348     -      - 
Saskatchewan Assistance Program  773  1.319 (1.142 – 1.524) 1.209 (1.042 – 1.402) 0.012 
Family-based    345  1.399 (1.130 – 1.731) 1.250 (1.004 – 1.555) 0.046 
Senior-based    4374  0.899 (0.840 – 0.960) 1.041 (0.963 – 1.125) 0.313 
 
Number of physician visits 
during observation year 
None     328     -      - 
1-3     3654  0.892 (0.711 – 1.121) 0.863 (0.685 – 1.086) 0.207 
119 
4-11     13656  0.459 (0.368 – 0.573) 0.424 (0.339 – 0.531) <0.0001 
12+     8202  0.407 (0.325 – 0.508) 0.355 (0.283 – 0.446) <0.0001 
 
Index Year 
1994     2547     -      -  
1995     2744  0.964 (0.864 – 1.075) 0.958 (0.857 – 1.070) 0.445 
1996     2678  0.927 (0.831 – 1.035) 0.935 (0.836 – 1.045) 0.238 
1997     3028  0.848 (0.762 – 0.944) 0.872 (0.781 – 0.972) 0.014 
1998     2902  0.870 (0.781 – 0.970) 0.884 (0.792 – 0.987) 0.028 
1999     2947  0.741 (0.665 – 0.827) 0.763 (0.683 – 0.853) <0.0001 
2000     3045  0.832 (0.723 – 0.897) 0.862 (0.772 – 0.961) 0.008 
2001     2972  0.805 (0.723 – 0.897) 0.835 (0.748 – 0.933) 0.001 
2002     2977  0.686 (0.615 – 0.765) 0.711 (0.636 – 0.795) <0.0001 
 
Concurrent non-AHT medications   
during observation year 
None     10712     -       - 
1-2     12446  1.031 (0.978 – 1.088) 1.216 (1.144 – 1.292) <0.0001 
3-4     2374  1.036 (0.946 – 1.135) 1.405 (1.253 – 1.575) <0.0001 
5+     308  0.825( 0.649 – 1.047) 1.281 (0.983 – 1.670) 0.067 
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Predictor     n  Unadjusted OR  Adjusted OR  P Value 
       (95% CI)   (95% CI) 
 
 
Specific therapies during  
observation year 
Oral hypoglycemic or insulin 
   No     25546     -      -  
   Yes     294  0.515 (0.395 – 0.671) 0.532 (0.405 – 0.699) <0.0001 
Nitrates   
   No     24844     -      - 
   Yes     996  0.810 (0.709 – 0.926) 0.950 (0.824 – 1.094) 0.473 
Statin   
   No     24398     -      - 
   Yes     1442  0.548 (0.486 – 0.618) 0.579 (0.511 – 0.656) <0.0001 
ASA   
   No     25412     -      - 
   Yes     428  0.735 (0.599 – 0.902) 0.779 (0.629 – 0.966) 0.023 
Warfarin  
   No     25579     -      - 
   Yes     261  0.618 (0.472 – 0.810) 0.776 (0.588 – 1.024) 0.073 
Antidepressant    
   No     22139     -      - 120 
   Yes     3701  1.230 (1.147 – 1.320) 1.142 (1.051 – 1.240) 0.002 
 
Chronic disease score   25840  0.970 (0.956 – 0.983) 0.99 (0.98 – 1.00)  <0.0001 
 
a.     Cumulative gap measure  
b.     None, no income security benefits; SAP, a program of last resort for families and individuals who, for various reasons, including disability, illness, low income or unemployment, cannot meet basic living costs;  Family-based, 
supplements the financial resources of low-income families with dependent children – eligibility based on annual family income and assets; Senior-based, supplementary income for subjects ≥65 years who have little or no income 
other than the federal Old Age Security pension and Guaranteed Income Supplement 
AHT  Antihypertensive  
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 Overall BB ACEI ARB CCB 
(Non-DHP) 
CCB 
(DHP) 
Thiazides BB + 
Thiazide  
ACEI + 
HCTZ  
ARB + 
HCTZ 
 
K-sparing 
+ HCTZ 
P-
Valuea 
Subjects 
(%) 
 
36214 6907 
(19.1) 
 
8623 
(23.8) 
1600 
(4.4) 
1170 
(3.2) 
2111 
(5.8) 
5690 
(15.7) 
126 
(0.4) 
553 
(1.5) 
453 
(1.3) 
8980 
(24.8) 
 
Mean age (years) at index 
(SD) 
 
59.1 
(12.7) 
55.9 
(11.8) 
59.2 
(12.1) 
58.0 
(11.4) 
60.0 
(12.4) 
61.9 
(12.6) 
61.1 
(13.5) 
58.2 
(10.8) 
58.4 
(10.8) 
59.8 
(11.9) 
59.0 
(13.6) 
<0.0001 
Male (%) 
 
14576 
(40.2) 
2842 
(41.1) 
4566 
(53.0) 
 
849 
(53.1) 
544 
(46.5) 
995 
(47.2) 
1692 
(29.7) 
67 
(53.2) 
302 
(54.5) 
23 
(51.9) 
2477 
(27.6) 
<0.0001 
Mean CDS at index (SD) 
 
2.9 
(1.8) 
 
2.1 
(1.6) 
3.9 
(1.6) 
 
3.0 
(1.7) 
3.8 
(2.2) 
3.0 
(1.8) 
1.9 
(1.7) 
1.6 
(1.3) 
3.8 
(1.5) 
2.8 
(1.4) 
2.9 
(1.7) 
<0.0001 
Index year (%) 
   1994 
   1995 
   1996 
   1997 
   1998 
   1999 
   2000 
   2001 
   2002 
 
3313 (9.1) 
3583 (9.9) 
3476 (9.6) 
4029(11.1) 
3888(10.7) 
4221(11.7) 
4507(12.4) 
4566(12.6) 
4631(12.8) 
 
 
 
551 (8.0) 
673 (9.7) 
729 (10.6) 
807 (11.7) 
863 (12.5) 
888 (12.9) 
845 (12.2) 
776 (11.2) 
775 (11.2) 
 
746 (8.7) 
928 (10.8) 
842 (9.8) 
1001(11.6) 
800 (9.3) 
951 (11.0) 
1023(11.9) 
1103(12.8) 
1229(14.3) 
 
 
0 (0) 
0 (0) 
2 (0.1) 
50 (3.1) 
122 (7.6) 
258 (16.1) 
328 (20.5) 
407 (25.4) 
433 (27.1) 
 
 
187 (16.0) 
199 (17.0) 
130 (11.1) 
122 (10.4) 
127 (10.9) 
113 (9.7) 
104 (8.9) 
98 (8.4) 
90 (7.7) 
 
 
271 (12.8) 
242 (11.5) 
168 (8.0)  
223 (10.6) 
242 (11.5) 
208 (9.9) 
258 (12.2) 
279 (13.2) 
220 (10.4) 
 
  
 
400 (7.0) 
386 (6.8) 
403 (7.1) 
524 (9.2) 
608 (10.7) 
744 (13.1) 
849 (14.9) 
861 (15.1) 
915 (16.1) 
 
 
12 (9.5) 
17 (13.5) 
22 (17.5) 
13 (10.3) 
11 (8.7) 
13 (10.3) 
13 (10.5) 
19 (15.1) 
6 (4.8) 
 
 
20 (3.6) 
24 (4.3) 
31 (5.6)  
65 (11.7) 
54 (9.7) 
76 (13.7) 
110 (19.9) 
95 (17.1) 
79 (14.3) 
 
 
0 (0) 
0 (0) 
0 (0)  
8 (1.8) 
26 (5.7) 
38 (8.4) 
64 (14.1) 
104(23.0) 
213(47.0) 
 
 
1126(12.5) 
1114(12.4) 
1149(12.8) 
1216(13.5) 
1035(11.5) 
932(10.4) 
913(11.5) 
824(10.2) 
671(9.2) 
 
<0.0001 
Physician visitsb in  
observation year (%) 
   0 
   1-3 
   4-11 
   12+ 
 
 
 
349 (1.0) 
4496(12.4) 
20423(56.4) 
10946(30.2) 
 
 
 
66 (1.0) 
781 (11.3) 
3617 (52.4) 
2443 (35.4) 
 
 
100 (1.2) 
1076(12.5) 
5092(59.1) 
2355(27.3) 
 
 
18 (1.1) 
180 (11.2) 
1010(63.1) 
392 (24.5) 
 
 
10 (0.9) 
107 (9.1) 
596 (51.0) 
457 (39.0) 
 
 
26 (1.2) 
278 (13.2) 
1150(54.5) 
657 (31.1) 
 
 
49 (0.1) 
745 (13.1) 
3265 (57.4) 
1631 (28.7) 
 
 
0 (0) 
23 (18.3) 
67 (53.2) 
36 (28.6) 
 
 
7 (1.3) 
71 (12.8) 
357 (64.4) 
119 (21.5) 
 
 
6 (1.3) 
52 (11.5) 
295(65.0) 
100(22.2) 
 
 
67 (0.7) 
1183(12.4) 
4974(55.4) 
2756(30.7) 
 
 
<0.0001 
Total concurrent non-AHT 
medications in observation 
year (%) 
   0 
   1-2 
   3-4 
   5+ 
 
 
 
 
15077(41.6) 
16334 (45.1) 
4051 (11.2) 
752 (2.1) 
 
 
 
2606 (37.7) 
3220 (46.6) 
911 913.2) 
170 (2.5) 
 
 
 
 
3794(44.0) 
3782(43.9) 
899 (10.4) 
148 (1.7) 
 
 
 
728 (45.5) 
711 (44.4) 
137 (8.5) 
24 (1.5) 
 
 
 
321 (27.4) 
589 (50.4) 
202 (17.3) 
58 (5.0) 
 
 
 
 
913 (43.2) 
950 (45.0) 
194 (9.2) 
54 (2.6) 
 
 
 
2458 (43.2) 
2521 (44.3) 
612 (10.8) 
100 (1.8) 
 
 
 
58 (46.0) 
51 (40.5) 
14 (11.1) 
3 (2.4) 
 
 
 
278 (50.2)  
231 (41.7) 
39 (7.0) 
6 (1.1) 
 
 
 
221(48.7) 
191(42.3) 
38 (8.4) 
3 (0.7) 
 
 
 
 
3700(41.2) 
4088(25.0) 
1006(11.2) 
186 (2.1) 
 
 
 
<0.0001 
Table 5.3 Baseline Characteristics of Monotherapy Cohort (n=36,214)    
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Concurrent non-AHT 
medication in observation 
year (%) 
   Diabetes / Insulin 
   Nitrates 
   Statins 
   ASA 
   Warfarin 
   Antidepressants  
 
 
 
 
 
 
 
 
451 (1.2) 
1232 (3.4) 
2624 (7.2) 
648 (1.8) 
358 (1.0) 
4958 (13.7) 
 
 
 
 
33 (0.5) 
609 (8.8) 
430 (6.2) 
200 (2.9) 
89 (1.3) 
1460 (21.1) 
 
 
 
246 (2.9) 
137 (1.6) 
928 (10.8) 
127 (1.5) 
102 (1.2) 
819 (9.5) 
 
 
 
22 (1.4) 
10 (0.6) 
196 (12.2) 
13 (0.8) 
10 (0.6) 
162 (10.1) 
 
 
 
18 (1.5) 
272 (23.2) 
85 (7.3) 
55 (4.7) 
34 (2.9) 
211 (18.0) 
 
 
 
15 (0.7) 
82 (3.9) 
164 (7.8) 
48 (2.3) 
15 (0.7) 
219 (0.4) 
 
 
 
41 (0.7) 
42 (0.7) 
319 (5.6) 
74 (1.3) 
39 (0.7) 
745 (13.1) 
 
 
 
4 (3.2) 
1 (0.8) 
5 (4.0) 
3 (2.4) 
0 (0) 
12 (9.5) 
 
 
 
11 (2.0) 
10 (1.8) 
50 (9.0) 
12 (2.2) 
4 (0.7) 
62 (11.2) 
 
 
 
 
8 (1.8) 
3 (0.7) 
70 (15.5) 
5 (1.1) 
2 (0.4) 
43 (9.5) 
 
 
 
 
53 (0.6) 
66 (0.7) 
377 (4.2) 
111 (1.2) 
63 (0.7) 
1225(13.6) 
 
 
 
<0.0001 
Income security benefitsc 
(%) 
   None 
   SAP 
   Family-based 
   Senior-based 
 
 
 
28554 (78.8) 
1045 (2.9) 
400 (1.1) 
6215 (17.2) 
 
 
5665 (82.0) 
262 (3.8) 
105 (1.5) 
875 (12.7) 
 
 
6905(80.1) 
219 (2.5) 
93 (1.1) 
1406(16.3) 
 
 
1365(85.3) 
22 (1.4) 
25 (1.6) 
188 (11.8) 
 
 
924 (79.0) 
38 (3.9) 
13 (1.1) 
195 (16.7) 
 
 
1594(75.5) 
57 (2.7) 
13 (0.6) 
447 (21.2) 
 
 
4437 (78.0) 
123 (2.2) 
59 (1.0) 
1071 (18.8) 
 
 
94 (74.6) 
5 (4.0) 
6 (4.8) 
21 (16.7) 
 
 
436 (78.7) 
15 (2.7) 
4 (0.7) 
99 (17.9) 
 
 
 
362(84.3) 
4 (0.9) 
6 (1.3) 
61 (13.5) 
 
 
6752(75.2) 
300 (3.3) 
76 (0.8) 
1852(20.6) 
 
 
<0.0001 
a.   Overall test of significance that all 10 treatment groups are similar (ANOVA and Chi-square) 
b.   A single visit includes all services delivered to a single subject by a single physician for the same diagnosis on the same day at the same clinic/location 
None, no income security benefits; SAP, a program of last resort for families and individuals who, for various reasons, including disability, illness, low income or unemployment, cannot meet basic living costs;  Family-based,  
supplements the financial resources of low-income families with dependent children – eligibility based on annual family income and assets; Senior-based, supplementary income for subjects ≥65 years who have little or no income 
other than the federal Old Age Security pension and Guaranteed Income Supplement 
BB  Beta blockers 
ACEI  Angiotensin converting enzyme inhibitors 
ARB Angiotensin receptor blockers 
CCB  Calcium channel blockers 
DHP Dihydropyridine 
K Potassium  
HCTZ Hydrochlorothiazide  
122 
SD Standard deviation 
CDS Chronic disease score (Von Korff)26 
AHT Antihypertensive  
SAP Saskatchewan Assistance Program  
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Table 5.4. Predictors of Adherencea  (≥80%) for Monotherapy Cohort   
  
 
Predictor     n  Unadjusted OR  Adjusted OR  P Value 
       (95% CI)   (95% CI) 
 
Sex 
Male     14569     -      -       
Female     21645  0.922 (0.884 – 0.963) 1.175 (1.120 – 1.233) <0.0001   
 
Age     36214  1.013 (1.011 – 1.014) 1.011 (1.009 – 1.013) <0.0001 
 
Income Security Benefitb 
None     26472     -      - 
Saskatchewan Assistance Program  1240  0.773 (0.685 – 0.872) 0.962 (0.845 – 1.096) 0.562 
Family-based    905  0.670 (0.581 – 0.774) 0.770 (0.660 – 0.899) 0.001 
Senior-based    7597  1.109 (1.053 – 1.168) 1.011 (0.949 – 1.077) 0.727 
 
AHT Category 
ARB     1600     -      -    123 
Beta Blocker    6907  0.267 (0.238 – 0.299) 0.295 (0.262 – 0.333) <0.0001    
ACEI     8623  0.795 (0.712 – 0.887) 0.903 (0.805 – 1.014) 0.084 
CCB (Non-DHP)    1170  0.284 (0.242 – 0.333) 0.323 (0.273 – 0.381) <0.0001 
CCB (DHP)    2111  0.644 (0.564 – 0.735) 0.709 (0.617 – 0.813) <0.0001 
Thiazides     5690  0.296 (0.263 – 0.332) 0.293 (0.260 – 0.331) <0.0001 
Beta Blocker + Thiazide   126  0.544 (0.378 – 0.782) 0.653 (0.450 – 0.949) 0.025 
ACEI + HCTZ    554  0.949 (0.778 – 1.159) 1.052 (0.857 – 1.292) 0.627 
ARB + HCTZ     453  1.194 (0.957 – 1.490) 1.150 (0.916 – 1.443) 0.228 
K-sparing + HCTZ    8980  0.177 (0.158 – 0.198) 0.192 (0.170 – 0.216) <0.0001 
 
Number of physician visits 
during observation year 
None     349     -      - 
1-3     4496  1.894 (1.386 – 2.589) 2.177 (1.579 – 3.003) <0.0001 
4-11     20423  4.712 (3.470 – 6.398) 5.522 (4.030 – 7.567) <0.0001 
12+     10946  4.464 (3.284 – 6.068) 5.552 (4.043 – 7.624) <0.0001 
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Predictor     n  Unadjusted OR  Adjusted OR  P Value 
       (95% CI)   (95% CI) 
 
Index Year 
1994     3313     -      -  
1995     3583  1.028 (0.929 – 1.136) 1.003 (0.902 – 1.116) 0.953 
1996     3476  1.014 (0.916 – 1.122) 1.015 (0.912 – 1.116) 0.782 
1997     4029  1.180 (1.071 – 1.300) 1.117 (1.007 – 1.238) 0.036 
1998     3888  1.235 (1.120 – 1.361) 1.186 (1.070 – 1.316) 0.001 
1999     4221  1.519 (1.382 – 1.670) 1.371 (1.239 – 1.518) <0.0001 
2000     4507  1.584 (1.443 – 1.740) 1.365 (1.235 – 1.510)  <0.0001 
2001     4566  1.766 (1.609 – 1.938) 1.439 (1.302 – 1.591) <0.0001 
2002     4631  1.822 (1.660 – 1.999) 1.403 (1.268 – 1.551) <0.0001 
 
Concurrent non-AHT medications   
during observation year 
None     15077     -       - 
1-2     16334  1.047 (1.001 – 1.096) 0.936 (0.887 – 0.988) 0.017 
3-4     4051  1.082 (1.008 – 1.161) 0.909 (0.830 – 0.996) 0.040 
5+     752  1.072 (0.923 – 1.244) 0.886 (0.742 – 1.058) 0.182 
 
Specific therapies during  
observation year 
Diabetes or insulin 
   No     35763     -      -  
   Yes     451  1.515 (1.258 – 1.825) 0.995 (0.814 – 1.216) 0.959  
Nitrates   
   No     34982     -      - 
   Yes     1232  0.899 (0.799 – 1.011) 0.894 (0.783 – 1.019) 0.094 
Statin   
   No     33590     -      - 
   Yes     2624  2.089 (1.928 – 2.264) 1.607 (1.469 – 1.758) <0.0001 
ASA   
   No     35566     -      - 
   Yes     648  1.460 (1.250 – 1.706) 1.524 (1.285 – 1.806) <0.0001 
Warfarin  
   No     35856     -      - 
   Yes     358  1.185 (0.960 – 1.461) 1.003 (0.801 – 1.256) 0.979 
Antidepressant    
   No     31256     -      - 
   Yes     4958  0.843 (0.793 – 0.897) 0.931 (0.865 – 1.003) 0.059 
 
Chronic disease score   36214  1.092 (1.080 – 1.105) 0.985 (0.970 – 0.999)  0.040 
 
 
a. Cumulative gap measure  
b. None, no income security benefits; SAP, a program of last resort for families and individuals who, for various reasons, including disability, illness, low income or unemployment, cannot meet basic living costs;  Family-based, 
supplements the financial resources of low-income families with dependent children – eligibility based on annual family income and assets; Senior-based, supplementary income for subjects ≥65 years who have little or no income 
other than the federal Old Age Security pension and Guaranteed Income Supplement 
ACEI – Angiotensin converting enzyme inhibitors  ARB – Angiotensin receptor blockers  CCB – Calcium channel blockers DHP – Dihydropyridine AHT – Antihypertensive  
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Appendix C. Drugs Available for Inclusion in Analyses   
 
 
*Used for the Modified Proportion of Days Covered calculation  
Antihypertensive Agents 
  
Non-Antihypertensive Drug 
Categories a  
 
Single Entity Agents     
 
Beta Blockers 
   Acebutolol     
   Atenolol *    
   Metoprolol     
   Nadolol      
   Propanolol 
   Timolol 
 
ACEI 
   Benazepril     
   Captopril     
   Cilazepril     
   Enalapril     
   Fosinopril 
   Lisinopril* 
   Perindopril 
   Quinapril 
   Ramipril 
 
ARB 
   Candesartan     
   Eprosartan     
   Irbesartan     
   Losartan* 
   Telmisartan     
   Valsartan 
 
CCB (Non-DHP) 
   Diltiazem* 
   Verapamil 
 
CCB (DHP) 
   Amlodipine 
   Felodipine 
   Nifedipine SR* 
 
Thiazides 
   Chlorthalidone     
   HCTZ* 
   Indapamide 
   Metolazone  
 
 
Combination Agents  
 
Beta Blocker + Thiazide 
   Atenolol / Chlorthalidone* 
   Propanolol / HCTZ 
   Timolol / HCTZ 
 
ACEI + HCTZ 
   Cilazepril / HCTZ 
   Enalapril / HCTZ 
   Lisinopril / HCTZ* 
   Quinapril / HCTZ 
    
ARB + HCTZ 
   Candesartan / HCTZ 
   Irbesartan / HCTZ 
   Losartan / HCTZ* 
   Telmisartan / HCTZ 
   Valsartan / HCTZ 
 
K-sparing diuretic + HCTZ 
   Amiloride / HCTZ 
   Spironolactone / HCTZ  
   Triamterene / HCTZ* 
 
    
    
 
 
Cardiac agents 
Statins 
Other lipid agents 
Anticoagulants 
Antiplatelets 
Insulin 
Oral diabetes agents 
Glucose testing agents 
Antidepressants 
Older antipsychotics 
Newer antipsychotics  
Glucocorticosteroids 
   Oral 
   Inhaled 
   Parenteral  
Bisphosphonates 
HRT 
Uric acid agents 
Migraine agents 
NSAIDs 
Proton pump inhibitors  
H2 antagonists 
Misoprostol 
Other gastrointestinal agents 
Transplant  
 
 
 
 
a.  Drug class categorization determined by Saskatchewan Drug Plan personnel  
ACEI Angiotensin converting enzyme 
ARB Angiotensin receptor blocker 
CCB Calcium channel blocker 
DHP Dihydropyridine  
SR Slow release 
HCTZ Hydrochlorothiazide 
K Potassium  
HRT Hormone replacement therapy  
NSAID Non-steroidal anti-inflammatory drug 
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- Chapter 6 - 
 
SUMMARY 
 
6.1 Summary of Research 
Given its enormous economic and clinical impact, it is not surprising that a significant amount of 
research continues to be directed towards cardiovascular disease (CVD) risk-reduction.  
Recognizing the negative impact that non-adherence can have on the prevention and 
management of CVD, it is also understandable that a part of this research focuses on strategies to 
improve adherence.  Accessibility, frequent patient contact, and strong pharmacotherapy 
knowledge make pharmacists, especially those in primary care settings, an obvious choice to be 
involved in interventions aimed at CVD risk-reduction.   
 
Although studies have examined interventions involving pharmacists in CVD risk-reduction,1-6 
few have been implemented into practice.7  Challenges within the current practice environment 
including pharmacist shortages, lack of time, and remuneration models based on technical 
dispensing activities are possible reasons for this lack of uptake into real-world settings.  As 
such, it is still unknown what impact typical pharmacists can really have on cardiovascular risk-
reduction in today’s health care system.  Recognizing the challenges of today’s practice 
environment for pharmacists, the objective of this research program was to investigate strategies 
that typical pharmacists in primary care settings can implement to effectively facilitate 
cardiovascular risk reduction within the constraints of the current health care system.  This 
objective was achieved through four separate, but related studies, involving both interventional 
and observational research.   
 
Clinical pharmacy positions within medical clinics have traditionally been reserved for 
pharmacists who are specialized or hold post-graduate degrees.  Considering the majority of 
Canadian pharmacists hold baccalaureate degrees, the intent of the Collaborative Cardiovascular 
Risk-Reduction in Primary Care (CCARP) pilot study was to evaluate an intervention 
specifically designed for typical, non-specialist pharmacists who have the opportunity to work in 
a family physician practice.  The intervention, aimed at lowering global cardiovascular risk, was 
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purposely designed so that no significant extra training or specialization would be required of the 
pharmacist. 
 
Despite being a pilot study, CCARP is still one of the largest studies to date evaluating the 
impact of pharmacist involvement on cardiovascular risk reduction,3, 7, 21 and one of the few that 
evaluated a practical pharmacist intervention intended to be carried out by non-specialist 
pharmacists in typical (i.e. fee-for-service) practice settings.  Although a statistical difference 
was not shown in the primary endpoint, the intervention did appear to improve evidence-based 
drug utilization.   Furthermore, the study was able to demonstrate the feasibility of incorporating 
a non-specialist pharmacist into a busy family physician practice.   
 
To build on the lessons learned from the CCARP study, future studies are needed to clarify the 
effects of this approach.  In addition, certain study design modifications should be considered.  
First, subsequent studies should use a cluster-randomized approach, grouping patients by clinic, 
or at a minimum, by physician.  This would minimize the potential for contamination and allow 
researchers to draw more definite conclusions.  Also, although all patients enrolled in CCARP 
were classified as moderate-high risk for a cardiovascular event, many had good control of their 
risk factors at the time of entry into the study.  In order to increase the efficiency of future 
studies, we would recommend only enrolling those with uncontrolled risk factors.  Finally, to 
ensure that small, yet clinically significant improvements are detected, a composite primary 
endpoint, rather than a less sensitive risk score, like the Framingham score used in the CCARP 
study, would be more appropriate.  
 
Research into pharmacist involvement in CVD risk reduction has often focused on pharmacists 
in clinical settings.  However, since approximately 70% of Canadian pharmacists practice in 
community pharmacies, we were interested in identifying CVD research conducted in these 
settings.  Our systematic review of the literature demonstrated that CVD research has been 
occurring in community pharmacy settings for over 30 years.  Unfortunately, although the 
majority of the studies reviewed claimed to show a benefit, much of the research was of poor 
quality and did not demonstrate any clinically relevant benefit, making it difficult to determine 
the true impact of the pharmacist interventions.   
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The majority of community pharmacy interventions studied in the systematic review were 
complex and time-intensive, with a median contact time of 27 minutes.  Given the current 
pharmacist shortage, few community pharmacists would be able to devote that much time to a 
single patient while still managing the rest of their daily duties and responsibilities.  This issue of 
time commitment has frequently been ignored by investigators as only 3 of the 37 studies 
commented on the complexity and feasibility of their intervention.  Considering that time 
intensiveness appears to be a major barrier to the implementation of research findings into real 
world practice, further research is needed to develop high quality, efficient and effective 
strategies that can be implemented in today’s practice environment. 
 
Recognizing this, we designed the Community Pharmacy Assisting in Total Cardiovascular 
Health (CPATCH) study.  By doing so, we not only demonstrated the feasibility of designing a 
high quality, robust study involving community pharmacists, but also focused on an area known 
to have a significant impact on patient outcomes: medication adherence.8, 9  To optimize the 
efficiency of the CPATCH intervention, patients were objectively targeted at a time when they 
were most likely to become non-adherent.  Previous research suggests this critical time occurs 
during the first year, and at the first dispensation of therapy.10-13 The intervention was also 
specifically designed to not require any major time commitment or changes to existing workflow 
patterns, thereby maximizing its external validity to current community pharmacy environments.   
 
Although the CPATCH study design focuses on statin medications, the intervention and 
methodology is intended to be transferable to other medication classes.  For instance, the final 
study in this research program demonstrated that the patterns of first year non-adherence with 
antihypertensive medications are almost identical to those of statins.  Further observational 
studies examining adherence to other cardiovascular medication classes are needed to determine 
if these patterns are indeed consistent.  If so, it supports the application of the CPATCH strategy 
to a broader range of subjects and medications.   
 
Throughout this program of research, we demonstrated that non-specialist pharmacists in 
primary care settings can be involved in CVD risk reduction interventions; however, one specific 
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strategy did not emerge as superior.  What is apparent is the need for further high quality 
research, especially in the area of community pharmacy interventions.  It is also evident that 
additional research is required to determine how to maximize the uptake of research protocols 
into current practice.  This ‘baby-step’ approach to facilitating pharmacy practice change is 
complimentary to many current research programs that investigate activities in typical practice 
environments.  Finally, utilization and adherence to chronic medications are an obvious area 
where the profession of pharmacy can contribute significantly to advancing the quality of 
Canada’s health care system.     
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